1. Introduction {#sec1-jcm-09-01284}
===============

AKI is considered a complex disorder with increased morbidity, prolonged hospitalization and mortality especially in high risk patients that may be attributed to various causes (pre-renal; renal, i.e., intrinsic to the renal parenchyma; and post-renal), including the use of nephrotoxic medications such as contrast media (CM), dehydration, sepsis, renal surgery, renal ischemia, ischemia--reperfusion (IR) renal injury, and urinary tract obstruction \[[@B1-jcm-09-01284]\]. Criteria used for the diagnosis of AKI vary widely among studies in humans \[[@B2-jcm-09-01284]\], including percent change in the baseline serum creatinine (sCr) levels (e.g., an increase of variously 25--50%) and absolute elevation from baseline sCr level (e.g., an increase of variously 0.5--2.0 mg/dL) \[[@B3-jcm-09-01284]\]. These variable definitions have been addressed by two consensus groups, namely the Acute Dialysis Quality Initiative (ADQI) proposing the RIFLE (Risk, Injury, Failure, Loss and End-stage kidney disease) system \[[@B4-jcm-09-01284]\] and more recently the Acute Kidney Injury Network (AKIN), which have attempted to standardize the diagnosis of AKI irrespective of etiology. According to the AKIN diagnostic criteria \[[@B5-jcm-09-01284]\], AKI is an abrupt (within 48 h) reduction in human kidney function defined as occurrence of any of the following after a reno-toxic event: (a) absolute increase in sCr ≥ 0.3 mg/dL (≥ 26.4 μmol/L) or a percentage increase in sCr ≥ 50% (1.5-fold from baseline), which is known or presumed to have occurred within the prior seven days \[[@B6-jcm-09-01284]\]; or (b) a reduction in urine output (documented oliguria of \< 0.5 mL/kg/h for more than 6 h). This definition is in accordance with the current Clinical Practice Guideline for AKI by "Kidney Disease: Improving Global Outcomes" (KDIGO) \[[@B6-jcm-09-01284]\]. Nevertheless, a recent systematic review evaluating the methods used to investigate AKI biomarkers showed that results are difficult to interpret, not comparable, and not consistently reproducible due to the impact of the variable AKI definitions still used to determine the outcome of interest in human studies (38.0% of the studies used the AKIN; 21.4% used the RIFLE; 20.3% used the KDIGO; and 20.3% used another definition) \[[@B2-jcm-09-01284]\]. Similarly, variable definitions of AKI have been used in animal studies, a fact that has been recognized as an important limitation in translating preclinical findings in clinical studies \[[@B7-jcm-09-01284],[@B8-jcm-09-01284]\] among others \[[@B9-jcm-09-01284]\]. Several reviews of available animal models, including their advantages and disadvantages, have been discussed \[[@B10-jcm-09-01284]\]; however, the types of models are often incomplete and many details, such as model techniques and modeling time, are not mentioned. Currently proposed AKI models include, among others: IR renal injury, including shock wave lithotripsy (SWL); injection of drugs, toxins, or endogenous toxins; ureteral obstruction, contrast-induced nephropathy (CIN); trauma such as burn; etc. \[[@B10-jcm-09-01284],[@B11-jcm-09-01284],[@B12-jcm-09-01284],[@B13-jcm-09-01284],[@B14-jcm-09-01284],[@B15-jcm-09-01284],[@B16-jcm-09-01284]\].

Depending on the insult type, there are various mechanisms leading to renal damage such as renal vasoconstriction \[[@B17-jcm-09-01284]\], vascular endothelial damage, cytokine expression \[[@B18-jcm-09-01284]\], increase of IL-18, mediating acute tubular necrosis, caspase activity stimulation, p53 up-regulation \[[@B19-jcm-09-01284]\], accumulation of toxic metabolites \[[@B20-jcm-09-01284]\], mast cells/neutrophils activation, reactive oxygen species (ROS) generation causing lipid peroxidation that leads to cellular membrane destruction, excessive intracellular DNA breakdown, energy depletion, intracellular Ca2+ elevation, higher inducible nitric oxide (NO) synthase (iNOS) expression, NO deficiency, intra-parenchymal hemorrhage \[[@B21-jcm-09-01284]\], fibrosis, direct cellular toxicity, tubular obstruction, vascular congestion, activation of angiotensin II axis \[[@B22-jcm-09-01284]\], mitochondrial dysfunction \[[@B23-jcm-09-01284]\], cell cycle arrest in G2 phase, ATPase activity inhibition, and cellular transport modification. ROS activate pro-apoptotic proteins eventually promoting Bax translocation (regulated by PI3K/Akt pathway) to the outer mitochondrial membrane, causing the release of cytochrome c in the cytosol \[[@B24-jcm-09-01284]\]. Bax is also responsible for caspase 9 activation that activates caspase 3, triggering apoptosis. The tubular component of AKI consists of injured, necrotic/apoptotic cells falling into the lumen that cause obstruction/back leak of the filtrate to the interstitial space, inducing inflammation.

CIN is a real, albeit rare, entity in current clinical medical practice that represents a serious iatrogenic AKI form, occurring 24--72 h after administration of iodinated contrast media (CM) during angiographic or other procedures, such as urography \[[@B3-jcm-09-01284],[@B25-jcm-09-01284]\]. The exact pathophysiology of CIN is not fully elucidated but oxidative stress is considered a major mechanism in CIN \[[@B26-jcm-09-01284]\], and the identification of novel biomarkers that may more accurately detect renal function changes, reflect kidney damage, assist monitoring, and elucidate pathophysiology have attracted considerable scientific attention nowadays \[[@B27-jcm-09-01284]\]. CM passing through the kidney results in an intense tubular transport that increases the activity in the thick ascending limb of Henle's loop. This process increases oxygen consumption/metabolic activity of outer renal medulla, exacerbating the marginal hypoxic conditions. Prostanoids and NO are mainly responsible for the medullary vasodilatory response \[[@B28-jcm-09-01284]\]. Therefore, any NO deficit may contribute to an additional hypoxic renal insult. CIN and IR renal injury share common pathways regarding the vasodilatory potential of NO. IR renal injury is a common complication during renal transplantation/artery angioplasty, partial nephrectomy, cardiopulmonary/aortic bypass surgery, and others \[[@B29-jcm-09-01284]\]. In the IR renal injury setting, however, there are conflicting results reported, with some studies suggesting that NO induces cytotoxicity, and others showing that increased NOS activity is linked to increased renal blood flow in the ischemic region \[[@B30-jcm-09-01284]\]. NOSs are a family of enzymes catalyzing the production of NO from L-arginine. There are three isoforms: the endothelial NOS (eNOS), the neuronal NOS (nNOS), and the iNOS involved in immune response. In the IR renal injury, endogenous NO is synthesized by eNOS and iNOS \[[@B31-jcm-09-01284]\], while it is found that eNOS-mediated NO production plays a pivotal protective role in IR-induced AKI \[[@B1-jcm-09-01284]\]. IR renal injury is also closely linked to ROS generation/apoptosis.

Prevention and/or management of the various AKI forms, such as CIN, is mainly supportive at present, consisting of intravenous hydration \[[@B32-jcm-09-01284]\]. Even though the potential beneficial effects of many agents with antioxidant properties have been tested, the value of such substances other than sodium bicarbonate remains controversial \[[@B32-jcm-09-01284],[@B33-jcm-09-01284]\]. Phosphodiesterase 5 (PDE5) inhibitors (PDE5Is) are currently recommended as first-line therapy of erectile dysfunction (ED) by enhancing the vasodilatory effects of NO \[[@B34-jcm-09-01284]\]. Acting via the selective inhibition of cyclic guanosine monophosphate (cGMP)-specific PDE5 that metabolizes cGMP, the principal mediator of NO-induced smooth muscle relaxation, PDE5Is cause vasodilatation in the corpora cavernosa promoting erection ([Figure 1](#jcm-09-01284-f001){ref-type="fig"}). This class of drugs has shown beneficial potential through various mechanisms in some CIN animal models \[[@B33-jcm-09-01284]\]. The aim of this paper is to provide a comprehensive overview of the available literature on the potential reno-protective properties of PDE5Is in the various forms of AKI.

2. Experimental Section {#sec2-jcm-09-01284}
=======================

Medline (Ovid Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, and Ovid MEDLINE(R) 1946 to November 2019) was systematically searched to detect all relevant animal and human studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@B37-jcm-09-01284]\], using the following keyword combinations (Medical Subject Headings; MeSH): PDE5i or avanafil or benzamidenafil or dasantafil or icariin or lodenafil or mirodenafil or sildenafil or tadalafil or udenafil or vardenafil or zaprinast combined with renal or kidney or nephrotoxicity or contrast or CIN or AKI or nephrotoxic or cisplatin or aminoglycoside or trauma or acute kidney injury or NSAIDS or non-steroidal or shock or sepsis or hypoperfusion or hypovolaemia or hypovolemia or renal artery stenosis or obstruction or acute tubular necrosis or glomerulonephritis or nephritis or renal failure or adenine or cyclosporine. The specific literature search strategy used is available in [Appendix A](#app1-jcm-09-01284){ref-type="app"}. The reference lists of selected studies were screened for other potentially eligible studies. After excluding duplicates, citations in abstract form, and non-English citations, the titles/abstracts of full papers were screened for relevance, defined as original research focusing on the topic "nephropathy AND effects of phosphodiesterase 5 inhibitors". Studies focusing on alterations of renal function and/or structure for \>3 months (conventionally considered as following the KDIGO definition of chronic kidney disease (CKD) were excluded \[[@B6-jcm-09-01284]\]). Two review authors (G.G. and IE.Z.) independently scanned the title and the abstract content, or both, of every record retrieved to determine which studies should be assessed further evaluated and extracted all data. Disagreements were resolved through consensus or by consultation with a third author (C.M.). A final draft of the manuscript was prepared after several revisions and approved by all authors.

3. Results {#sec3-jcm-09-01284}
==========

In total, 83 studies were included for qualitative synthesis ([Figure 2](#jcm-09-01284-f002){ref-type="fig"}). Among the 11 natural/synthetic agents currently available (avanafil, benzamidenafil, dasantafil, icariin, lodenafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, and zaprinast), sildenafil is the most widely investigated (n = 42 studies), followed by tadalafil (n = 20 studies), icariin (n = 10 studies), vardenafil (n = 7 studies), zaprinast (n = 4 studies), and udenafil (n = 2 studies). No studies on lodenafil, benzamidenafil, mirodenafil, avanafil, or dasantafil were detected. Most of the studies (n = 79) used animal models, including among others currently proposed AKI models (IR renal injury, including SWL; injection of drugs, toxins, or endogenous toxins; ureteral obstruction; CIN; trauma such as burn; etc.) \[[@B10-jcm-09-01284],[@B11-jcm-09-01284],[@B12-jcm-09-01284],[@B13-jcm-09-01284],[@B14-jcm-09-01284],[@B15-jcm-09-01284],[@B16-jcm-09-01284]\] and variable definitions of AKI in line with the situation observed in human studies \[[@B2-jcm-09-01284]\]. Only four human studies were detected: two preclinical studies utilizing human tissue \[[@B24-jcm-09-01284],[@B38-jcm-09-01284]\] and two clinical trials \[[@B17-jcm-09-01284],[@B39-jcm-09-01284]\].

The reno-protective action of PDE5Is was evident in the vast majority of studies (n = 81), independently of the AKI type and the agent applied. Only one human study on sildenafil \[[@B39-jcm-09-01284]\] and one animal study on zaprinast \[[@B40-jcm-09-01284]\] failed to reveal any reno-protective action of PDE5Is, showing a neutral effect. PDE5Is appeared to be beneficial in AKI of various etiologies by improving renal functional/histopathological alternations through various mechanisms, such as affecting regional hemodynamics, cell expression, and mitochondrial response to oxidative stress and inflammation.

The main characteristics and results of the human studies evaluating the potential reno-protective effects of PDE5Is are summarized in [Table 1](#jcm-09-01284-t001){ref-type="table"} \[[@B17-jcm-09-01284],[@B24-jcm-09-01284],[@B38-jcm-09-01284],[@B39-jcm-09-01284]\]. The main characteristics and results of the animal studies on currently proposed AKI models evaluating the potential reno-protective effects of sildenafil, tadalafil, icariin, vardenafil, zaprinast--udenafil are summarized in [Table 2](#jcm-09-01284-t002){ref-type="table"} \[[@B23-jcm-09-01284],[@B30-jcm-09-01284],[@B41-jcm-09-01284],[@B42-jcm-09-01284],[@B43-jcm-09-01284],[@B44-jcm-09-01284],[@B45-jcm-09-01284],[@B46-jcm-09-01284],[@B47-jcm-09-01284],[@B48-jcm-09-01284],[@B49-jcm-09-01284],[@B50-jcm-09-01284],[@B51-jcm-09-01284],[@B52-jcm-09-01284],[@B53-jcm-09-01284],[@B54-jcm-09-01284],[@B55-jcm-09-01284],[@B56-jcm-09-01284],[@B57-jcm-09-01284],[@B58-jcm-09-01284],[@B59-jcm-09-01284],[@B60-jcm-09-01284],[@B61-jcm-09-01284]\], [Table 3](#jcm-09-01284-t003){ref-type="table"} \[[@B29-jcm-09-01284],[@B35-jcm-09-01284],[@B45-jcm-09-01284],[@B49-jcm-09-01284],[@B62-jcm-09-01284],[@B63-jcm-09-01284],[@B64-jcm-09-01284],[@B65-jcm-09-01284],[@B66-jcm-09-01284],[@B67-jcm-09-01284],[@B68-jcm-09-01284],[@B69-jcm-09-01284],[@B70-jcm-09-01284],[@B71-jcm-09-01284],[@B72-jcm-09-01284],[@B73-jcm-09-01284],[@B74-jcm-09-01284]\], [Table 4](#jcm-09-01284-t004){ref-type="table"} \[[@B18-jcm-09-01284],[@B75-jcm-09-01284],[@B76-jcm-09-01284]\], [Table 5](#jcm-09-01284-t005){ref-type="table"} \[[@B45-jcm-09-01284],[@B77-jcm-09-01284],[@B78-jcm-09-01284]\], and [Table 6](#jcm-09-01284-t006){ref-type="table"} \[[@B21-jcm-09-01284],[@B40-jcm-09-01284],[@B79-jcm-09-01284],[@B80-jcm-09-01284]\], respectively. The main characteristics and results of the animal studies in the AKI-CKD transition spectrum (focusing on renal function and/or structure alterations for up to three months, not fulfilling the KDIGO definition for CKD \[[@B6-jcm-09-01284]\]) evaluating the potential reno-protective effects of sildenafil, tadalafil, icariin, vardenafil, zaprinast--udenafil are summarized in [Table A1](#jcm-09-01284-t0A1){ref-type="table"} \[[@B19-jcm-09-01284],[@B81-jcm-09-01284],[@B82-jcm-09-01284],[@B83-jcm-09-01284],[@B84-jcm-09-01284],[@B85-jcm-09-01284],[@B86-jcm-09-01284],[@B87-jcm-09-01284],[@B88-jcm-09-01284],[@B89-jcm-09-01284],[@B90-jcm-09-01284],[@B91-jcm-09-01284],[@B92-jcm-09-01284],[@B93-jcm-09-01284],[@B94-jcm-09-01284],[@B95-jcm-09-01284],[@B96-jcm-09-01284],[@B97-jcm-09-01284],[@B98-jcm-09-01284]\], [Table A2](#jcm-09-01284-t0A2){ref-type="table"} \[[@B99-jcm-09-01284],[@B100-jcm-09-01284]\], [Table A3](#jcm-09-01284-t0A3){ref-type="table"} \[[@B22-jcm-09-01284],[@B101-jcm-09-01284],[@B102-jcm-09-01284],[@B103-jcm-09-01284],[@B104-jcm-09-01284]\], [Table A4](#jcm-09-01284-t0A4){ref-type="table"} \[[@B105-jcm-09-01284],[@B106-jcm-09-01284],[@B107-jcm-09-01284],[@B108-jcm-09-01284]\], and [Table A5](#jcm-09-01284-t0A5){ref-type="table"} \[[@B109-jcm-09-01284],[@B110-jcm-09-01284]\], respectively ([Appendix B](#app2-jcm-09-01284){ref-type="app"}).

4. Discussion {#sec4-jcm-09-01284}
=============

PDE5Is have received a lot of attention since the first drugs were launched in the market. Four potent selective agents (avanafil, sildenafil, tadalafil, and vardenafil) have been approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the treatment of ED \[[@B111-jcm-09-01284],[@B112-jcm-09-01284]\]. ED can be managed successfully with currently available treatment options, but it cannot be cured and most patients will be treated without cause-specific options, such as the use of PDE5Is \[[@B34-jcm-09-01284]\]. Exceptions are psychogenic, post-traumatic arteriogenic in young patients, and hormonal causes (e.g., hypogonadism) of ED, which are potentially curable with specific treatments that might be employed first, when such causes are detected \[[@B34-jcm-09-01284]\]. Consequently, treatment strategy of ED should be tailored depending on invasiveness, efficacy, safety, cost, and patient preference of the currently available options; in the context of this strategy, PDE5Is are currently recommended strongly as first-line treatment option given that lifestyle changes are initiated/risk factors are modified prior to or at the same time as initiating ED treatment \[[@B34-jcm-09-01284]\].

Other EMA/FDA approved indications of PDE5Is include pulmonary arterial hypertension (PAH) (sildenafil and tadalafil) and management of men with moderate to severe LUTS secondary to benign prostatic obstruction with or without ED (tadalafil) \[[@B34-jcm-09-01284],[@B113-jcm-09-01284],[@B114-jcm-09-01284],[@B115-jcm-09-01284]\]. Besides the aforementioned agents, there are other non-EMA/FDA approved PDE5Is including benzamidenafil, dasantafil, lodenafil, mirodenafil, and udenafil, some of which are commercially available in a few countries (lodenafil in Brazil; mirodenafil in South Korea; and udenafil in South Korea, Russia, and Philippines) \[[@B113-jcm-09-01284]\]. Other agents with weak PDE5I properties include icariin and zaprinast \[[@B116-jcm-09-01284]\]. Icariin, a prenylated flavonol glycoside extracted from plants of the *Epimedium* genus, has demonstrated PDE5I activity in vitro, enhancement of NO, and antioxidant activity \[[@B116-jcm-09-01284]\]. It has been widely used in Chinese traditional medicine. It shows peak concentration levels at 1 h and should be avoided in patients with bleeding disorders, hypotension, arrhythmias, and hormone-sensitive cancers (breast, ovarian, or prostate). Zaprinast is an inhibitor of PDE5, PDE6, PDE9, and PDE11. In the past, it has been used for the treatment of PAH and inhibition of malaria parasites. Zaprinast activates the G-protein coupled receptor, GPR35, that plays a crucial role in cardiovascular disease, pain, regulation of inflammation, hypertension, diabetes, and irritable bowel disease \[[@B117-jcm-09-01284],[@B118-jcm-09-01284]\]. The main characteristics of PDE5Is are summarized in [Table 7](#jcm-09-01284-t007){ref-type="table"} \[[@B34-jcm-09-01284],[@B112-jcm-09-01284],[@B113-jcm-09-01284],[@B119-jcm-09-01284],[@B120-jcm-09-01284],[@B121-jcm-09-01284],[@B122-jcm-09-01284],[@B123-jcm-09-01284],[@B124-jcm-09-01284],[@B125-jcm-09-01284]\].

PDE5Is interfere selectively with cGMP hydrolysis by PDE5, increasing intracellular cGMP, which results in smooth muscle relaxation/raised arterial blood flow improving penile erection. PDE5 belongs to a superfamily of enzymes that convert intracellular cAMP/cGMP into the consonant nucleotides. It is a cytosolic protein with three isoforms expressed in various organs apart from the penis (corpora cavernosa), including kidney (vessels, glomeruli, inner medullary collecting ducts, and cortical tubules) that specifically degrades cGMP \[[@B66-jcm-09-01284]\]. In particular, PDE5A1 and PDE5A2 are widely expressed in tubular epithelial cells of the renal proximal tubule and medullary collecting duct, as well as in vascular smooth muscle cells, platelets, brain, and lung, while PDE5A3 is only expressed in vascular smooth muscle cells \[[@B126-jcm-09-01284]\].

Cyclic nucleotide signal transduction pathways represent an emerging research field in kidney disease, with selective PDE5 inhibition attracting ongoing interest nowadays \[[@B127-jcm-09-01284]\]. Current evidence supports the notion that regulation of the cGMP -dependent protein kinase 1-PDE signaling pathway may be reno-protective and that its regulation might provide novel, therapeutic strategies for chronic kidney disease with selective PDE5Is having shown potential in treating kidney fibrosis, while possessing antithrombotic and anticancer activity \[[@B128-jcm-09-01284]\]. In this respect, PDE5Is represent a potential but still understudied/controversial option against various forms of AKI such as CIN \[[@B28-jcm-09-01284]\], given that NO/cGMP are crucial mediators in renal vasculature and NO is an essential endogenous vasodilator for medullary oxygenation \[[@B33-jcm-09-01284]\].

The mechanism of action of PDE5Is in the prevention and management of AKI is still not fully elucidated. Multiple mechanisms have been proposed to play a role in counteracting the cascade of changes caused by the renal injury. Stimulation of NO production through NOS, medullary blood flow improvement, protection against vascular endothelial damage, Bcl2/Bax ratio reversal, ERK phosphorylation, mitochondrial biogenesis activation, renal progenitor cell upregulation, and the regulation of multiple signaling pathways such as insulin/IGF1, T17/Treg, PI3K/Akt, and NF-kB \[[@B75-jcm-09-01284]\] are the most well-described mechanisms through which PDE5Is offer protection. The increased ERK phosphorylation boosts NOS activity and subsequent rapid NO release \[[@B30-jcm-09-01284]\]. The repairing process following any renal injury requires energy provided by the cellular mitochondria. Mitochondria are continuously regenerated but cellular injury such as sepsis and hypoxia induce rapid biogenesis. This process is mediated by a transcriptional co-activator, peroxisome proliferator-activated receptor γ co-activator 1a (PGC-1a). PGC-1a activates the nuclear respiratory factors 1 and 2, which eventually activate mitochondrial transcription factor A that is responsible for the transcription of mitochondrial DNA \[[@B23-jcm-09-01284],[@B67-jcm-09-01284]\]. An alternative process that PDE5Is activate to promote recovery from renal injury is the renal progenitor cell stimulation. PDE5Is, more specifically icariin, upregulates HGF, WT-1, and BMP-7, which lead to an increased number of CD133^+^ and CD24^+^, cells that are capable of self-renew and also differentiate into podocytes or tubular cells \[[@B57-jcm-09-01284],[@B103-jcm-09-01284]\]. In addition to the aforementioned actions, PDE5Is are likely to exert their protective effect through an alternative pathway. PDE5Is increase cGMP, which activates protein kinase G that opens mitochondrial K~ATP~ channels that induce depolarization of the mitochondrial inner membrane and Mg^2+^ release. The depolarized membrane results in reduced Ca^2+^ influx; therefore, suppressed cellular death and increased Mg^2+^ concentration reduces ROS and lessens p38 MAPK activation, which is responsible for apoptosis \[[@B30-jcm-09-01284],[@B88-jcm-09-01284],[@B129-jcm-09-01284]\]. The most common reno-protective mechanisms of PDE5Is are summarized in [Figure 3](#jcm-09-01284-f003){ref-type="fig"}.

To the best of our knowledge, this is the first review that attempts in a systematic way to define the reno-protective potential of PDE5Is in the various forms of AKI. Based on our results, it appears that sildenafil is the most widely PDE5I studied in AKI among the 11 natural/synthetic agents currently available (avanafil, benzamidenafil, dasantafil, icariin, iodenafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, and zaprinast).

The reno-protective effects of PDE5Is have been evaluated in four human studies to date (preclinical studies using human cells: n = 2 \[[@B24-jcm-09-01284],[@B38-jcm-09-01284]\]; clinical studies: n = 2 \[[@B17-jcm-09-01284],[@B39-jcm-09-01284]\]) ([Table 1](#jcm-09-01284-t001){ref-type="table"}). In one study, human umbilical cord mesenchymal stem cells (huMSC), which have a high self-renewal/multi-directional differentiation potential, were treated with icariin and administered in an animal model of renal injury induced by adenine \[[@B38-jcm-09-01284]\]. Blood urea nitrogen/sCr analysis showed amelioration of functional parameters. Icariin-treated huMSC increased the number of cells in injured renal tissues, reduced fibrosis, oxidative damage, inflammatory responses, and promoted expression of growth factors protecting injured renal tissue. In another study, cisplatin was added to human embryonic kidney (HEK)-293 renal cell cultures pre-treated with icariin \[[@B24-jcm-09-01284]\]. The authors concluded that icariin prevents cisplatin-induced HEK-293 cell injury by inhibiting oxidative stress, inflammatory response, and cellular apoptosis partly via regulating nuclear factor kappa-like chain-enhancer of activated B cells (NF-κB) and PI3K/Akt signaling pathways. In a non-randomized clinical trial, 49 patients with renal tumors were submitted to open nephron-sparing surgery after renal artery clamping \[[@B17-jcm-09-01284]\]. Twenty-two patients were pre-treated with tadalafil one day pre- and two days post-operatively and 27 patients underwent the same surgery without receiving tadalafil. Renal artery clamping induced kidney dysfunction reflected by increases in urinary NGAL and KIM-1 (two novel biomarkers for AKI) in all participants. Tadalafil reduced the urinary excretion of KIM-1, but not of NGAL. The incidence of AKI was comparable between groups but sCr elevation was significantly attenuated in the tadalafil-treated group compared to controls. It was concluded that tadalafil exerts reno-protective effects in AKI following nephron-sparing surgery. In a randomized placebo-controlled trial, 40 patients were submitted to robot-assisted partial nephrectomy after hilar clamping. The reno-protective effect of a single 100 mg oral dose of sildenafil immediately prior to clamping was evaluated \[[@B39-jcm-09-01284]\]. GFR was similarly decreased between arms during the immediate postoperative period and at an intermediate-term follow-up of six months; the reno-protective effect of sildenafil was not evident in this study (neutral effect).

All animal studies investigating the potential reno-protective effect of sildenafil (n = 41) manifested a beneficial effect, irrespectively of the mechanism of AKI; almost all parameters evaluated (biochemical or morphological) were reported to improve ([Table 2](#jcm-09-01284-t002){ref-type="table"} and [Table A1](#jcm-09-01284-t0A1){ref-type="table"}). Similarly, all animal studies investigating the potential reno-protective effect of tadalafil (n = 19) revealed beneficial outcomes (attenuated histopathological changes/improved biochemical profile; [Table 3](#jcm-09-01284-t003){ref-type="table"} and [Table A2](#jcm-09-01284-t0A2){ref-type="table"}). Two studies provided comparative results for sildenafil and tadalafil, demonstrating the superiority of the former against tubular cell apoptosis, oxidative status, lipid peroxidation and NOS alterations \[[@B45-jcm-09-01284],[@B49-jcm-09-01284]\]. Unique proteins, cells, and genes have been utilized to investigate the aftermath following icariin's administration as a reno-protective agent, such as connective tissue growth factor, TUNEL positive cells, nephrin, α-smooth muscle actin, E-cadherin, LY6G, F4/80, NLRP3, NF-κΒ, etc. All available animal studies evaluating icariin (n = 8) showed a beneficial effect (oxidative injury reversal, obliteration of renal function impairment, and improvement of renal hemodynamics/NO sensitivity; [Table 4](#jcm-09-01284-t004){ref-type="table"} and [Table A3](#jcm-09-01284-t0A3){ref-type="table"}). Similar to sildenafil/tadalafil, icariin suspends the inflammatory response initiation as well as the alteration of the cellular phase and preserves renal morphology. Finally, vardenafil, zaprinast, and udenafil have been investigated in a limited number of studies (n = 7, n = 4, and n = 2, respectively), almost all of which show antioxidant, anti-inflammatory, and reno-protective effects ([Table 5](#jcm-09-01284-t005){ref-type="table"}, [Table 6](#jcm-09-01284-t006){ref-type="table"}, [Table A4](#jcm-09-01284-t0A4){ref-type="table"}, and [Table A5](#jcm-09-01284-t0A5){ref-type="table"}). In one study, vardenafil was compared to sildenafil and tadalafil in an animal model of partial unilateral ureteric obstruction, reporting that all agents were beneficial with sildenafil showing best results \[[@B45-jcm-09-01284]\]. Only one study failed to demonstrate any beneficial effect from zaprinast pre-treatment in an animal model of nephrectomy and concomitant contra-lateral renal hilar occlusion \[[@B40-jcm-09-01284]\]. Even though data are still limited, especially in humans with inconclusive or negative results of only two clinically relevant studies available at present, the results of animal studies are promising and have already fueled clinical research, which is on-going with results expected to come out in the near future \[[@B122-jcm-09-01284]\]. Nevertheless, the potential reno-protective capacity of PDE5Is in AKI warrants further investigation in clinical trials.

5. Conclusions {#sec5-jcm-09-01284}
==============

PDE5Is appear to be beneficial in AKI of various etiologies by improving renal functional/histopathological alternations through various mechanisms, such as by affecting regional hemodynamics, cell expression, and mitochondrial response to oxidative stress and inflammation. The reno-protective action of PDE5Is was evident in the vast majority of the studies, independently of the AKI type and the agent applied. Even though data are still limited, especially in humans with inconclusive or negative results of only two clinically relevant studies available at present, the results of animal studies are promising. The potential reno-protective capacity of PDE5Is in AKI warrants further investigation in clinical trials.
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jcm-09-01284-t0A1_Table A1

###### 

Animal studies evaluating the potential reno-protective effects of sildenafil.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference\                  Studied Animal                                    Model                                                                       PDE5I Route                                                Timing         Sample                                                         Renal Injury Effects                                                                                                                                                                                                       PDE5I Renal Effects                                                                               Outcome
  /Country/Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  --------------------------- ------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------- -------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------
  \[[@B81-jcm-09-01284]\]/\   Male Sprague Dawley rats                          5/6 nephrectomy                                                             Sildenafil\                                                POST           8 weeks\                                                       ↑sCr, ↑SBP, ↑proteinuria\                                                                                                                                                                                                  ↓sCr, ↓SBP, ↓proteinuria\                                                                         POS
  Venezuela/2005\                                                                                                                                           Orally\                                                                                                                                  ↓urinary NOX, ↓cGMP\                                                                                                                                                                                                       ↑ urinary NOX, ↑cGMP\                                                                             
                                                                                                                                                            2.5 mg/kg/day\                                                                                                                           Glomerulosclerosis\                                                                                                                                                                                                        All changes improved especially if PDE5i was given early                                          
                                                                                                                                                            Either immediately after nephrectomy for 8 weeks\                                                                                        Tubulo-interstitial damage\                                                                                                                                                                                                                                                                                                  
                                                                                                                                                            Or 4 weeks after nephrectomy for 4 weeks                                                                                                 Macrophage accumulation\                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                     Increased number of apoptotic cells                                                                                                                                                                                                                                                                                          

  \[[@B82-jcm-09-01284]\]/\   Laboratory large-white pigs                       Right single nephrectomy after 45 min of vascular clamping\                 Sildenafil\                                                PRE            0/15/30/45/60\                                                 ↓RVF, ↑RVR, ↓NO\                                                                                                                                                                                                           ↑↓RVF, ↓RVR, ↑NO\                                                                                 POS
  Spain/2007\                                                                   + Auto-transplantation\                                                     Orally\                                                                   min after unclamping                                           Minimal differences in tubular and endothelial structure                                                                                                                                                                   Minimal differences in tubular and endothelial structure                                          
                                                                                + Left nephrectomy                                                          100 mg, 2 h pre-op                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  \[[@B83-jcm-09-01284]\]/\   Adult male Wistar albino rats                     L-NAME\                                                                     Sildenafil\                                                POST           At 4 weeks\                                                    ↓NO, ↓cGMP\                                                                                                                                                                                                                ↑NO, ↑cGMP\                                                                                       POS
  Egypt/2008\                                                                   Orally\                                                                     Orally\                                                                                                                                  Glomerular collapse/mesangial matrix expansion with minimal cellular proliferation                                                                                                                                         Improvement in histological alterations                                                           
                                                                                50 mg/kg/day for 4 weeks                                                    5 mg/kg/day\                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                            2 weeks after L-NAME for 2 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                      

  \[[@B84-jcm-09-01284]\]/\   Laboratory minipigs                               Right single nephrectomy after 45 min of vascular clamping\                 Sildenafil\                                                PRE            0/15/30/45/60\                                                 ↓RVF, ↓RVR\                                                                                                                                                                                                                ↑RVF, ↓ RVR, ↑NO\                                                                                 POS
  Spain/2009\                                                                   +Auto-transplantation\                                                      Orally\                                                                   min after unclamping                                                                                                                                                                                                                                                                      Reduced tubular edema, Improved endothelial cell integrity and mitochondrial ultrastructure       
                                                                                +Left nephrectomy                                                           100 mg, 1.5 h pre-op                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  \[[@B85-jcm-09-01284]\]/\   Male Sprague Dawley                               Streptozotocin\                                                             Sildenafil\                                                POST           At 8 weeks                                                     ↑glucose, ↑urine output\                                                                                                                                                                                                   ↑glucose, ↓urine output\                                                                          POS
  Korea/2009\                                                                   Single intravenous dose 60 mg/kg\                                           Orally\                                                                                                                                  ↑urine 8-OH dG\                                                                                                                                                                                                            ↓urine 8-OH dG\                                                                                   
                                                                                                                                                            3 mg/kg/day\                                                                                                                             ↑urine albumin\                                                                                                                                                                                                            ↓urine albumin\                                                                                   
                                                                                                                                                            For 8 weeks                                                                                                                              ↑Kidney/BW ratio, ↑iNOS\                                                                                                                                                                                                   ↓Kidney/BW ratio, ↓iNOS\                                                                          
                                                                                                                                                                                                                                                                                                     ↑Nitrotyrosine, ↑MCP-1 ↑ED-1\                                                                                                                                                                                              ↓Nitrotyrosine, ↓MCP-1, ↓ED-1                                                                     

  \[[@B86-jcm-09-01284]\]/\   Male Sprague Dawley rats                          Unilateral Nephrectomy and 1 week later DOCA strip 200 mg/kg implantation   Sildenafil\                                                POST           At 4 weeks                                                     ↑mortality, ↑SBP, ↑ Kidney weight\                                                                                                                                                                                         ↓mortality, ⇔ SBP, ↓Kindey weight\                                                                POS
  Korea/2012                                                                                                                                                Orally\                                                                                                                                  ↓CrCl, ↑sCr, ↑FeNa, ↑ACR\                                                                                                                                                                                                  ↑CrCl, ↓sCr, ↓FeNa, ↓ACR ↓aSMA\                                                                   
                                                                                                                                                            50 mg/kg/day\                                                                                                                            ↑ED-1, ↑BAX, ↓Bcl2, ↑aSMA, ↑TGF-b1\                                                                                                                                                                                        ↓ED-1, ↓BAX, ↑Bcl2, ↓TGF-b1\                                                                      
                                                                                                                                                            2 weeks after DOCA for 2 weeks                                                                                                           ↑TUNEL +ve, ↑fibronectin\                                                                                                                                                                                                  ↓TUNEL +ve, ↓fibronectin\                                                                         
                                                                                                                                                                                                                                                                                                     ↑mRNA TGF-β1/MCP-1\                                                                                                                                                                                                        ↓mRNA TGF-β1/MCP-1/↓ mRNA ICAM1\                                                                  
                                                                                                                                                                                                                                                                                                     ↑ICAM 1t\                                                                                                                                                                                                                  Reversed all renal injuries                                                                       
                                                                                                                                                                                                                                                                                                     Tubular casts/Tubular obstruction/Vessel dilatation/Glomerulosclerosis/interstitial expansion                                                                                                                                                                                                                                

  \[[@B87-jcm-09-01284]\]/\   Male Wistar rats                                  5/6 nephrectomy                                                             Sildenafil\                                                POST           Every 2 weeks                                                  ↑Kidney hypertrophy\                                                                                                                                                                                                       ↓Kidney hypertrophy\                                                                              POS
  Venezuela/2012\                                                                                                                                           Orally\                                                                                                                                  ↑Proteinuria, ↓NO2/NO3 ↓GMP (urine) ↑Nitrotyrosine                                                                                                                                                                         ↓Proteinuria,\                                                                                    
                                                                                                                                                            5 mg/kg/day for 60 days\                                                                                                                                                                                                                                                                                                                                            ↑NO2/NO3\                                                                                         
                                                                                                                                                            24 h after nephrectomy                                                                                                                                                                                                                                                                                                                                              ↑cGMP (urine) ↓Nitrotyrosine                                                                      

  \[[@B19-jcm-09-01284]\]/\   Male Wistar rats                                  Cyclosporine A\                                                             Sildenafil\                                                POST           At 21st day--urine sample/blood sample/renal tissue excision   ↑BUN, ↑sCr, ↑MDA levels\                                                                                                                                                                                                   ↓BUN, ↓sCr, ↓MDA levels\                                                                          POS
  Egypt/2013\                                                                   Subcutaneously\                                                             Orally\                                                                                                                                  ↑Urine Albumin/Cr\                                                                                                                                                                                                         ↓Urine Albumin/Cr, ↑eNOS\                                                                         
                                                                                20 mg/kg/day\                                                               5 mg/kg/day\                                                                                                                             ↓GSH/NO/catalase activity\                                                                                                                                                                                                 ↑GSH/NO/catalase activity\                                                                        
                                                                                21 days\                                                                    21 days\                                                                                                                                 ↑iNOS, TNF-a, Caspase 3 activity\                                                                                                                                                                                          ↓iNOS, TNF-a, Caspase 3 activity\                                                                 
                                                                                                                                                                                                                                                                                                     Tubular degeneration and dilation and necrosis/Glomerulat damage/Congestion\                                                                                                                                               Improved all histological changes                                                                 
                                                                                                                                                                                                                                                                                                     Dilated Bowman's space/Hemorrhage                                                                                                                                                                                                                                                                                            

  \[[@B88-jcm-09-01284]\]/\   Porcine kidneys                                   20 min warm ischemia followed by 2 or 18 h of cold storage                  Sildenafil\                                                PRE and POST   Samples during reperfusion                                     ↓RBF, ↑intrarenal resistance\                                                                                                                                                                                              ↑RBF, ↓intrarenal resistance\                                                                     POS
  United Kingdom/2014\                                                                                                                                      Intravenously\                                                                                                                           ↓Urine cGMP ↑ sCr\                                                                                                                                                                                                         ↑Urine cGMP, ↓sCr\                                                                                
                                                                                                                                                            1.4 mg/kg\                                                                                                                               Steady increase of K+\                                                                                                                                                                                                     \                                                                                                 
                                                                                                                                                            10 min prior to injury and 20min after reperfusion                                                                                       ↑Tubular injury\                                                                                                                                                                                                           No significant difference in K+\                                                                  
                                                                                                                                                                                                                                                                                                     No difference in groups\                                                                                                                                                                                                   No effect on tubular injury\                                                                      
                                                                                                                                                                                                                                                                                                     \                                                                                                                                                                                                                          regarding GAL/Endothelin1 Slight improvement of histological                                      
                                                                                                                                                                                                                                                                                                     Tubular dilatation and debris and interstitial edema/Ischemic changes                                                                                                                                                                                                                                                        

  \[[@B89-jcm-09-01284]\]/\   C57BL/6 mice                                      Left renal artery clamping for 2 weeks                                      Sildenafil\                                                POST           4 weeks                                                        Left kidney atrophy (clipped)\                                                                                                                                                                                             ↓Left kidney atrophy\                                                                             POS
  Brazil/2014\                                                                                                                                              Orally\                                                                                                                                  Right kidney hypertrophy\                                                                                                                                                                                                  ↓Right kidney hypertrophy\                                                                        
  \[[@B90-jcm-09-01284]\]/\                                                                                                                                 40 mg/kg/day\                                                                                                                            \                                                                                                                                                                                                                          \                                                                                                 
  Brazil/2014\                                                                                                                                              2 weeks post op for 2 weeks                                                                                                              ↓BW, ↑SBP, ↑HR\                                                                                                                                                                                                            Normal BW, ↓SBP, ↓HR\                                                                             
                                                                                                                                                                                                                                                                                                     ↑Intrarenal angiotensin I/II\                                                                                                                                                                                              ↓Intrarenal angiotensin I/II\                                                                     
                                                                                                                                                                                                                                                                                                     ⇔Plasma angiotensin I/II/1-7\                                                                                                                                                                                              ↑Plasma angiotensin 1-7\                                                                          
                                                                                                                                                                                                                                                                                                     ↓NO, ↑ONOO-, ↑O2-\                                                                                                                                                                                                         ↑NO, ↓ONOO-, ↓O2-\                                                                                
                                                                                                                                                                                                                                                                                                     Impaired vasodilation response to Ach                                                                                                                                                                                      Normal vasodilation response to Ach                                                               

  \[[@B91-jcm-09-01284]\]/\   White albino male rats                            Streptozocin\                                                               Sildenafil\                                                POST           8 weeks\                                                       ↓SOD, ↑TGF-β1, ↓NO, ↑sCr\                                                                                                                                                                                                  ↑SOD, ↓TGF-β1, ↑NO, ↓sCr\                                                                         POS
  Egypt/2016\                                                                   Single intraperitoneal\                                                     Orally\                                                                                                                                  ↑BUN, ↑proteinuria\                                                                                                                                                                                                        ↓BUN, ↓proteinuria\                                                                               
                                                                                dose 55 mg/kg                                                               3 mg/kg/day\                                                                                                                             ↑Kidney IL-1β\                                                                                                                                                                                                             ↓Kidney IL-1β\                                                                                    
                                                                                                                                                            For 8 weeks after Diabetic nephropathy                                                                                                   ↑Advanced glycation end products (AGEPs)                                                                                                                                                                                   ↓Advanced glycation end products (AGEPs)                                                          

  \[[@B92-jcm-09-01284]\]/\   Sprague-Dawley rats                               Streptozocin\                                                               Sildenafil\                                                POST           At 28th and 70th day                                           ↑sCr, ↑BUN, ↓CrCl\                                                                                                                                                                                                         ↓sCr, ↓BUN, ↑CrCl\                                                                                POS
  India/2016                                                                    Single intraperitoneal\                                                     Orally\                                                                                                                                  ↑Total protein excretion ↑albumin (urine)\                                                                                                                                                                                 ↓Total protein excretion\                                                                         
                                                                                dose 60 mg/kg                                                               2.5 mg/kg/day for 6 weeks after 28 days                                                                                                  Bowman's capsule thickening, glomerular sclerosis                                                                                                                                                                          ↓albumin (urine)\                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Histopathology improvement                                                                        

  \[[@B93-jcm-09-01284]\]/\   Male CD-1 mice                                    Streptozotocin\                                                             Sildenafil\                                                POST                                                                          ↑Glucose (urine), ↑MAP, ↓GFR\                                                                                                                                                                                              ↓Urine glucose, ↓MAP, ↑GFR\                                                                       POS
  Italy/2017                                                                    Single intraperitoneal dose 150 mg/kg                                       Intraperitoneally\                                                                                                                       ↑urinary ACR, ↑NGAL, ↑RRI\                                                                                                                                                                                                 ↓urinary ACR, ↓NGAL, ↓RRI\                                                                        
                                                                                                                                                            1.6 mg/kg\                                                                                                                               ↓Renal volume, ↓BMP7\                                                                                                                                                                                                      ↑Renal volume, ↑BMP7, ↓miR-22\                                                                    
                                                                                                                                                            3 days after STZ, for 4 weeks                                                                                                            ↑suPAR, ↑Vascular leakage\                                                                                                                                                                                                 ↓suPAR, ↓Vascular leakage\                                                                        
                                                                                                                                                                                                                                                                                                     ↑FITC-dextran extravasation\                                                                                                                                                                                               ↓FITC-dextran extravasation\                                                                      
                                                                                                                                                                                                                                                                                                     Reduced glomerular diameter/focal and segmental hyperplasia with diffuse mesangial proliferation/increased mesangial matrix deposition/acute tubular degeneration/eosinophilia/proximal tubule basal membrane thickening   Reduced mesangial matrix deposition                                                               

  \[[@B94-jcm-09-01284]\]/\   Adult male Sprague-Dawley rats                    Doxorubicin\                                                                Sildenafil\                                                POST                                                                          ↑Urea, ↑sCr, ↑uric acid ↑MDA, ↓GSH, ↑TNF-a ↑caspase-3\                                                                                                                                                                     ↓Urea, ↓sCr,\                                                                                     POS
  Egypt/2017\                                                                   Intraperitoneally\                                                          Orally\                                                                                                                                  Eosinophilic casts, tubule degeneration, vacuolization, endothelial cell edema                                                                                                                                             ↓uric acid ↓MDA, ↑GSH, ↓TNF-a ↓caspase-3\                                                         
                                                                                3.5 mg/kg\                                                                  5 mg/kg/day for 21 days                                                                                                                                                                                                                                                                                                                                             Histological improvement                                                                          
                                                                                Twice weekly for 3 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  \[[@B95-jcm-09-01284]\]/\   Nulliparous pregnant female Sprague-Dawley rats   L-NAME\                                                                     Sildenafil\                                                POST           Gestational Day 19                                             ↑BP, ↑Urine excretion\                                                                                                                                                                                                     ↓BP\                                                                                              POS
  South Africa/2017                                                             Orally\                                                                     Orally\                                                                                                                                  ↑Urinary nephrin mRNA\                                                                                                                                                                                                     ↓Urinary nephrin mRNA\                                                                            
                                                                                0.3 g/L (drinking water)\                                                   10 mg/kg\                                                                                                                                ↑Podocin (urine), ↑sFlt-1(mRNA)\                                                                                                                                                                                           ↓Podocin (urine)\                                                                                 
                                                                                4-8 days for EOPE\                                                          4-8 days for EOPE\                                                                                                                       ↓VEGF (mRNA), ↓PIGF\                                                                                                                                                                                                       ↓sFlt-1 (mRNA)\                                                                                   
                                                                                +\                                                                          8-14 days for LOPE                                                                                                                       Glomerular and tubular damage and mononuclear cell infiltration                                                                                                                                                            ↑VEGF (mRNA), ↑PIGF levels\                                                                       
                                                                                8-14 days for LOPE                                                                                                                                                                                                                                                                                                                                                                                                                              Attenuated histopathological changes                                                              

  \[[@B96-jcm-09-01284]\]/\   Rats                                              Adriamycin\                                                                 Sildenafil\                                                POST           Immortalized mouse podocytes\                                  ↑TRPC6 expression\                                                                                                                                                                                                         ↓TRPC6 expression, ↓Ca2+ influx\                                                                  POS
  Netherlands/2017                                                              Or\                                                                         Orally\                                                                   +\                                                             ↓Nephrin, ↑Glomerular desmin\                                                                                                                                                                                              ↑Nephrin ↓Glomerular desmin\                                                                      
                                                                                Streptozocin                                                                5 mg/kg/day for 6 weeks                                                   Mouse kidney cortex                                            ↑Urinary albumin\                                                                                                                                                                                                          ↓Urinary albumin                                                                                  
                                                                                                                                                                                                                                                                                                     ↑Glomerular lesions                                                                                                                                                                                                                                                                                                          

  \[[@B97-jcm-09-01284]\]/\   Male\                                             Adenine (0.25% w/w) orally\                                                 Sildenafil\                                                SIM            At Day 5\                                                      ↑BUN, sCr, uric acid, P, NGAL,\                                                                                                                                                                                            ↓BUN, sCr, uric acid, ↓P, NGAL,\                                                                  POS
  Oman/2018                   Sprague-Dawley rats                               Daily for 5 weeks                                                           Orally\                                                                                                                                  ↑total NO, IS, Caspase 3 +ve cells\                                                                                                                                                                                        ↓total NO, IS,\                                                                                   
                                                                                                                                                            (0.1, 0.5 or 2.5 mg/kg)\                                                                                                                 ↑Albumin, NAG activity\                                                                                                                                                                                                    ↓Caspase 3 +ve cells\                                                                             
                                                                                                                                                            Daily for 5 weeks (alone or concomitantly with adenine)\                                                                                 ↓Osmolality, CrCl in urine\                                                                                                                                                                                                ↓Albumin,\                                                                                        
                                                                                                                                                                                                                                                                                                     ↓CAT, glutathione reductase, SOD\                                                                                                                                                                                          ↓ NAG activity\                                                                                   
                                                                                                                                                                                                                                                                                                     ↓TAC, ↑MAPK\                                                                                                                                                                                                               ↑Osmolality,\                                                                                     
                                                                                                                                                                                                                                                                                                     ↑Fibrosis\                                                                                                                                                                                                                 ↓CrCl in urine\                                                                                   
                                                                                                                                                                                                                                                                                                     ↑Adiponectin, cystatin-C, TNF-a\                                                                                                                                                                                           ↑CAT, SOD\                                                                                        
                                                                                                                                                                                                                                                                                                     ↓Sclerostin, ↑MDA\                                                                                                                                                                                                         ↓glutathione reductase,\                                                                          
                                                                                                                                                                                                                                                                                                     Tubular necrosis, tubular dilatation, tubular cast formation, necrotic nuclei, tubular cells apoptosis, cellular shedding, mononuclear infiltration                                                                        ↑TAC, ↓MAPK, ↓Fibrosis\                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ↓Adiponectin, cystatin-C, TNF-a\                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ↑Sclerostin (not 0.1 mg/kg) ↓MDA\                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Improved tubular necrosis, tubular dilatation, tubular cast formation, mononuclear infiltration   

  \[[@B98-jcm-09-01284]\]/\   Male albino rats Sprague-Dawley                   Streptozotocin\                                                             Sildenafil\                                                POST           Day 16 after initiation of Sildenafil                          ↑sCr, ↑BUN\                                                                                                                                                                                                                ↓sCr, ↓BUN\                                                                                       POS
  Egypt/2018                                                                    Single intraperitoneal dose 45 mg/kg                                        Orally: 3 mg/kg/Day 3 weeks after STZ for 15 days                                                                                        ↑fasting and post prandial glucose\                                                                                                                                                                                        ↓fasting and post prandial glucose\                                                               
                                                                                                                                                                                                                                                                                                     ↓insulin levels\                                                                                                                                                                                                           ↑insulin levels\                                                                                  
                                                                                                                                                                                                                                                                                                     ↑insulin resistance\                                                                                                                                                                                                       ↓insulin resistance (insignificant)\                                                              
                                                                                                                                                                                                                                                                                                     ↑MDA, ↓GSH, ↓CAT, ↓GPx,\                                                                                                                                                                                                   ↓MDA, ↑GSH, ↑CAT, ↑GPx, ↑SOD, ↑TAC                                                                
                                                                                                                                                                                                                                                                                                     ↓SOD, ↓TAC                                                                                                                                                                                                                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; ACR, albumin-creatinine ratio; aSMA, α-smooth muscle actin; Bax, proapoptotic protein; Bcl-2, antiapoptotic gene; BP, blood pressure; BUN, blood urea nitrogen; BW, body weight; Ca^2+^, calcium; CAT, catalase; cGMP, cyclic guanosine monophosphate; CrCl, creatinine clearance, ED-1, monoclonal antibody, eNOS, endothelial NOS, FeNa, fractional excretion of sodium, FITC, fluorescein isothiocyanate, GFR, glomerular filtration rate; GPx, glutathione peroxidase; GSH, glutathione; HR, heart rate; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; IS, indoxyl sulfate; iNOS, inducible NOS; K, potassium; MAP, mean arterial pressure; MAPK, mitogen-activated protein kinase; MCP-1, monocyte chemoattractant protein 1; MDA, malondialdehyde; Na, sodium; NAG, N-acetyl-beta-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; NO, nitric oxide; NOX, NADPH oxidase; P, phosphorus; PDE5I, phosphodiesterase 5 inhibitor; PIGF, placenta growth factor; RRI, renal resistive index; RVF, renal vascular flow; RVR, renal vascular resistance; sCr, serum creatinine; sFlt1, soluble fms-like tyrosine kinase-1; SOD, superoxide dismutase; SBP, systolic blood pressure; suPAR, soluble urokinase-type plasminogen activator receptor; TAC, total antioxidant capacity; TGF-β1, transforming growth factor beta 1; TRPC6, transient receptor potential cation channel 6; TNF-a, tumor necrosis factor a; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; VEGF, vascular endothelia growth factor; 8-OH dG, 8-hydroxydeoxyguanosine; ↓, reduced; ↑, increased.

jcm-09-01284-t0A2_Table A2

###### 

Animal studies evaluating the potential reno-protective effects of tadalafil.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                  Studied Animal        Model       PDE5I Route                Timing   Sample                                  Renal Injury Effects                       PDE5I Renal Effects                 Outcome
  Country/Year                                                                                                                                                                                                              
  ---------------------------- --------------------- ----------- -------------------------- -------- --------------------------------------- ------------------------------------------ ----------------------------------- ---------
  \[[@B99-jcm-09-01284]\]/\    Male\                 SWL model   Tadalafil\                 PRE      Nephrectomy at Day 1/3/7                Loss of micro-villi\                       Reduced all histological damage\    POS
  Turkey/2013                  Sprague Dawley rats               *[Orally:]{.ul}*1 mg/kg\                                                    Tubular degeneration and necrosis\         \                                   
                                                                 Single dose\                                                                Interstitial edema and fibrosis\           ↓HSP-70                             
                                                                 150 min prior to SWL                                                        ↑ HSP-70                                                                       

  \[[@B100-jcm-09-01284]\]/\   Male Sprague Dawley   SWL model   Tadalafil\                 PRE      Bilateral nephrectomy 7 days post SWL   Renal tubular damage\                      Significantly less tissue damage\   POS
  Turkey/2017                                                    *[Orally:]{.ul}*1 mg/kg\                                                    Peritubular fibrosis/Loss of microvilli\   ⇔HSP-70 (glomerular)\               
                                                                 60 min prior to SWL                                                         ↑HSP-70                                    ↓HSP-70 (medullar/cortical)         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: AKI, acute kidney injury; HSP-70, heat shock protein 70; PDE5I, phosphodiesterase 5 inhibitor; SWL, shock wave lithotripsy; ↓, reduced; ↑, increased ⇔, no change.

jcm-09-01284-t0A3_Table A3

###### 

Animal studies evaluating the potential reno-protective effects of icariin.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                  Studied Animal              Model                             PDE5I Route                                 Timing   Sample                  Renal Injury Effects                                                   PDE5I Renal Effects                                                         Outcome
  Country/Year                                                                                                                                                                                                                                                                                                               
  ---------------------------- --------------------------- --------------------------------- ------------------------------------------- -------- ----------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------- ---------
  \[[@B101-jcm-09-01284]\]/\   Male Sprague--Dawley rats   Streptozotocin\                   Icariin\                                    POST     Day 7\                  ↑sCr, ↑BUN, ↑Glucose, ↑MDA, ↑Hyp, ↓SOD, ↑Collagen IV, ↑TGF-β1\         ↓sCr, ↓BUN, ↓MDA, ↓Hyp ↑SOD, ↓Collagen IV, ↓TGF-β1\                         POS
  China/2011\                                              Single Dose\                      Orally\                                              and\                    Glomerular Hypertrophy\                                                Inhibited these changes                                                     
                                                           Intravenously\                    80 mg/kg\                                            Week 13                 Expansion of mesangial area and ECM\                                                                                                               
                                                           40 mg/kg                          For 8 weeks\                                                                                                                                                                                                                    
                                                                                             From 5th to 20th week post streptozotocin                                                                                                                                                                                       

  \[[@B102-jcm-09-01284]\]/\   Male Sprague-Dawley rats    5/6 right nephrectomy\            Icariin\                                    POST     24 h before AKI\        ↑BUN,↑sCr, ↑ urinary protein\                                          ↓BUN, ↓sCr, ↓urinary protein\                                               POS
  Chiana/2014                                              model                             *Orally*\                                            and at Week 12          ↑Apoptotic rate, ↑Bcl-2, ↑Bax ↓G0/G1 phase cells\                      ↓Apoptotic rate, ↓Bcl-2, ↓Bax\                                              
                                                                                             20 + 40 mg/kg/day\                                                           ↑S phase cells                                                         ⇔G0/G1 phase cells, ↑G2/M phase\                                            
                                                                                             1 week after AKI for 12 weeks                                                                                                                       ↓ S phase cells                                                             

  \[[@B103-jcm-09-01284]\]/\   Male Sprague Dawley rats    1st stage: Partial nephrectomy\   Icariin\                                    POST     At 8 weeks              ↑BUN, ↑sCr, ↑uric acid\                                                ↓BUN, ↓sCr, ↓uric acid\                                                     POS
  China/2015                                               2nd stage: Right renal ligation   *Orally*\                                                                    Mesangial expansion/Edema\                                             ↑Renal progenitor cell proliferation\                                       
                                                                                             40 mg/kg/day\                                                                Basement membrane thickening and capillary compression/occlusion.\     ↓TGF-β1\                                                                    
                                                                                             8 weeks                                                                      Glomerular sclerosis/fibrosis\                                         Significantly improved glomerular lesions and blunted rest of the changes   
                                                                                                                                                                          Inflammatory cell infiltration                                                                                                                     

  \[[@B22-jcm-09-01284]\]/\    Female Wistar rats          Pregnancy induced hypertension\   Icariin\                                    POST     BP: Days 1 and 18\      ↑SBP (Day 18), ↑ BUN, ↑sCr\                                            ↓SBP (high dose), ↓BUN, ↓sCr\                                               POS
  China/2017                                               L-NAME 0.5 g/L\                   *Orally*\                                            Kidney tissue: Day 18   ↑Proteinuria, ↓Pup weight\                                             ↓Proteinuria (medium/high dose)\                                            
                                                           from Day 12 of gestation          10/50/100 mg/kg\                                                             ↓Nephrinm, ↑Ang II, ↑AGT\                                              No difference in pup weight\                                                
                                                                                             18 days of gestation                                                         Mesangial expansion\                                                   ↑Nephrin, ↓Ang II, ↓AGT\                                                    
                                                                                                                                                                          Basement membrane thickening                                           Markdely reduced severity of lesions                                        

  \[[@B104-jcm-09-01284]\]/\   MRL/lpr mice                K/O mice                          Icariin\                                    POST     Every 2 weeks\          ↑Urine protein,↑IgG deposit\                                           ↓Urine protein, ↓IgG deposit\                                               POS
  China/2018\                                                                                Orally\                                                                      ↑sCr, ↑BUN, ↑TNF-a\                                                    ↓sCr, ↓BUN, ↓TNF-a\                                                         
                                                                                             10 mg/kg/day\                                                                ↑Serum anti-dsDNA\                                                     ↓Serum anti-dsDNA\                                                          
                                                                                             8 weeks                                                                      ↑Translocation and phosphorylation of NF-kBp65\                        ↓Translocation and phosphorylation of NF-kBp65\                             
                                                                                                                                                                          ↑F4/80, ↑NLRP3, ↑caspase 1p20\                                         ↓F4/80, ↓NLRP3, ↓caspase 1p20\                                              
                                                                                                                                                                          Increased glomerular proliferation/sclerosis/peripheral inflammation   Improved all changes                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; Ang II, angiotensin II; Anti-dsDNA, antibody to double stranded DNA; AGT, angiotensinogen; Bax, proapoptotic protein; Bcl-2, antiapoptotic gene; BP, blood pressure; BUN, blood urea nitrogen; F4/80, macrophage marker; Hyp, hydroxyproline; IgG, immunoglobulin G; MDA, malondialdehyde; PDE5I, phosphodiesterase 5 inhibitor; SBP, systolic blood pressure; sCr, serum creatinine; SOD, superoxide dismutase; TGF-β1, transforming growth factor beta 1; TNF-a, tumor necrosis factor a; ↓, reduced; ↑, increased.

jcm-09-01284-t0A4_Table A4

###### 

Animal studies evaluating the potential reno-protective effects of vardenafil.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                  Studied Animal             Model                                        PDE5I Route                 Timing         Sample                                   Renal Injury Effects                                              PDE5I Renal Effects                       Outcome
  Country/Year                                                                                                                                                                                                                                                                                         
  ---------------------------- -------------------------- -------------------------------------------- --------------------------- -------------- ---------------------------------------- ----------------------------------------------------------------- ----------------------------------------- ---------
  \[[@B105-jcm-09-01284]\]/\   Sprague Dawley rats        Mouse monoclonal anti-Thy 1 antibody ER-4\   Vardenafil\                 PRE and POST   24-h urine collection on Days 2 and 6\   ↑PDE5-A, ⇔sCr\                                                    ↑cGMP, ↓TSP-1, ⇔sCr\                      POS
  Germany/2008                                            Single injection, 1 mg/kg                    *Orally*\                                  Blood sample: Day 6                      ↑proteinuria\                                                     ↓proliferation/cell number(glomerular)\   
                                                                                                       20 mg/kg within 18 h and\                                                           Mesangial proliferation                                           ↓collagen IV/fibronectin (glomerular)\    
                                                                                                       10 mg/kg/day for 48 h                                                                                                                                 ↓TGF-β activation ⇔proteinuria            

  \[[@B106-jcm-09-01284]\]/\   New Zealand Rabbits        Invagination of ureter in renal pelvis       Vardenafil\                 POST           8 weeks                                  Dilated renal pelvises\                                           Dilated renal pelvises\                   POS
  China/2009                                                                                           *Orally*\                                                                           Fibrotic PUJ\                                                     Less fibrotic PUJ\                        
                                                                                                       0.3 mg/kg/day\                                                                      ↑TGF-β1 ↓nNOS                                                     ↓TGF-β1 ↑nNOS                             
                                                                                                       For 8 weeks post op                                                                                                                                                                             

  \[[@B107-jcm-09-01284]\]/\   Sprague Dawley male rats   Streptozotocin\                              Vardenafil\                 POST           8 weeks after AKI                        ↓cGMP,\                                                           ↑cGMP\                                    POS
  Hungary/2013                                            Single intraperitoneal dose\                 *Orally*\                                                                           NCS elevated Urea levels\                                         Developed kidney hypertrophy\             
                                                          60/mg/kg                                     10 mg/kg/day for 8 weeks\                                                           Decreased body weight\                                            No difference in MAP\                     
                                                                                                       72 h post STZ                                                                       No difference in MAP\                                             ↓Urine protein/creatinine ratio\          
                                                                                                                                                                                           ↑Urine protein/creatinine ratio\                                  ↓Fibronectin, ↓TGF-β1\                    
                                                                                                                                                                                           ↑Fibronectin, ↑TGF-β1, ↑desmin, ↓nephrin, ↑Nitrotyrosine, ↑NOS\   ↓desmin, ↑nephrin\                        
                                                                                                                                                                                           Glomerular hypertrophy\                                           No difference\                            
                                                                                                                                                                                           Mesangial expansion\                                              Attenuated all changes                    
                                                                                                                                                                                           Adhesions to Bowman's capsule\                                                                              
                                                                                                                                                                                           Tubular dilatation and atrophy\                                                                             
                                                                                                                                                                                           Mononuclear cell infiltration                                                                               

  \[[@B108-jcm-09-01284]\]/\   Male Swiss albino mice     Cyclosporine A\                              Vardenafil\                 PRE            At 28 days\                              ↓Kidney weight\                                                   No change in kidney weight\               POS
  Turkey/2015                                             30 mg/kg\                                    *Orally*\                                                                           ↑BUN, ↑sCr, ↑TOS levels\                                          ↓BUN, ↓sCr, ↓TOS levels\                  
                                                          Subcutaneously\                              30 mg/kg/day\                                                                       ↓TAS levels,↓tissue NO\                                           ↑TAS levels, ↑tissue NO\                  
                                                          Daily for 28 days                            For 28 days                                                                         ↓COX-1, ↓COX-2, ↓TGF-β1\                                          ↑COX-1, ↑COX-2, ⇔TGF-β1\                  
                                                                                                                                                                                           ↓Pgp levels, ↓PDGF-A, ↓PDGF-C\                                    ↑Pgp levels, ↑PDGF-A, ↑PDGF-C\            
                                                                                                                                                                                           Histological changes: cortex/outer medulla                        Normal histopathological appearances      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; BUN, blood urea nitrogen; cGMP, cyclic guanosine monophosphate; COX, cyclo-oxygenase; FeNa, fractional excretion of sodium; MAP, mean arterial pressure; NCS, not clinically significant; NO, nitric oxide, nNOS, neuronal NOS; PDE5I, phosphodiesterase 5 inhibitor; PDGF, platelet-derived growth factor; Pgp, P glycoprotein; PUJ, pelvic ureteric junction; sCr, serum creatinine; TAS, total antioxidant status; TGF-β1, transforming growth factor beta 1; TOS, total oxidant status; TSP-1, thrombospondin -1; ↓, reduced; ↑, increased ⇔, no change.

jcm-09-01284-t0A5_Table A5

###### 

Animal studies evaluating the potential reno-protective effects of zaprinast and udenafil.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                  Studied Animal                    Model                                                                            PDE5I Route                        Timing         Sample                                         Renal Injury Effects                                                                                                           PDE5I Renal Effects            Outcome
  Country/Year                                                                                                                                                                                                                                                                                                                                                                                                   
  ---------------------------- --------------------------------- -------------------------------------------------------------------------------- ---------------------------------- -------------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------------------ ---------
  \[[@B109-jcm-09-01284]\]/\   Mongrel dogs                      Cut left renal nerves and electrostimulation of left renal bundle (distal end)   Zaprinast\                         SIM            Simultaneously                                 ↓Urine flow, ↓U~Na~V, ↓FeNa\                                                                                                   ↑Urine flow, ↑U~Na~V, ↑FeNa\   POS
  Japan/1998                                                                                                                                      *Intra-renal arterial infusion*\                                                                 ⇔RBF, ⇔GFR                                                                                                                     ⇔ RBF, ⇔GFR, ↓RVR\             
                                                                                                                                                  10 or 100 μg/kg/min                                                                                                                                                                                                             ↑Renal venous cGMP             

  \[[@B110-jcm-09-01284]\]/\   10-week-old male Sprague-Dawley   Right nephrectomy\                                                               Udenafil\                          SIM and POST   On Day 28 blood samples and left nephrectomy   ↑BUN, ↑sCr, ↓eNOS, ⇔VEGF\                                                                                                      ↓BUN, ↓sCr, ↑eNOS, ⇔VEGF\      POS
  Korea/2010                                                     + Left renal artery clamping for 45 min\                                         *Orally: 10 mg/kg*\                                                                              Decreased thickness of the proximal tubules and nuclei, vacuolization of the cytoplasm, altered cellular shape, fewer nuclei   ↓VEGF mRNA\                    
                                                                 and\                                                                             For 28 days after the procedure                                                                                                                                                                                                                                
                                                                 Cyclosporine A\                                                                                                                                                                                                                                                                                                                                 
                                                                 15 mg/kg subcutaneously                                                                                                                                                                                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; BUN, blood urea nitrogen; cGMP, cyclic guanosine monophosphate; eNOS, endothelial NOS; FeNa, fractional excretion of sodium; GFR, glomerular filtration rate; PDE5I, phosphodiesterase 5 inhibitor; RBF, renal blood flow; RVR, renal vascular resistance; sCr, serum creatinine; UNaV, urinary sodium excretion; VEGF, vascular endothelia growth factor; ↓, reduced; ↑, increased ⇔, no change.

![PDE5I-induced smooth muscle relaxation in the corpora cavernosa. cGMP is the principal mediator of NO-induced smooth muscle relaxation/vasodilation \[[@B35-jcm-09-01284]\]. cGMP propels a series of intracellular changes including inhibition of Ca^2+^ entry into the cell, Ca^2+^ shift into the endoplasmic reticulum, activation of K^+^ channels leading to membrane hyperpolarization, and stimulation of a cGMP-dependent protein kinase that activates a myosin light chain phosphatase. All these actions promote smooth muscle relaxation. NO penetrates the cytoplasm of smooth muscle cells binding to guanylyl cyclase (sGC), which catalyzes the enzymatic conversion of GTP to cGMP. Elevation of cGMP stimulates cGMP-dependent protein kinase G leading to PDE5 phosphorylation/activation. PDE5 hydrolyzes cGMP in the cavernosal tissue. Inhibition of PDE5 results in smooth muscle relaxation with increased arterial blood flow, leading to compression of the sub-tunical venous plexus followed by penile erection \[[@B36-jcm-09-01284]\].](jcm-09-01284-g001){#jcm-09-01284-f001}

![PRISMA flow chart showing the study selection procedure.](jcm-09-01284-g002){#jcm-09-01284-f002}

![Reno-protective mechanisms of PDE5Is.](jcm-09-01284-g003){#jcm-09-01284-f003}

jcm-09-01284-t001_Table 1

###### 

Human studies evaluating the potential reno-protective effects of phosphodiesterase 5 inhibitors.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference\                  Type of Study                                              AKI Model                      PDE5I Route                                         Timing         Sample                                      AKI Renal Effects                                 PDE5I Renal Effects                       Outcome
  Country/Year                                                                                                                                                                                                                                                                                                                     
  --------------------------- ---------------------------------------------------------- ------------------------------ --------------------------------------------------- -------------- ------------------------------------------- ------------------------------------------------- ----------------------------------------- ---------
  \[[@B24-jcm-09-01284]\]/\   Preclinical study on HEK-293 cell culture                  Cisplatin\                     Icariin\                                            PRE            Centrifuged at 4 °C, 10,000 g, for 20 min   Reduced viability, ↑p-NF-Kb\                      Improved viability, ↓p-NF-kB\             POS
  China/2019                                                                             Various doses\                 Various doses\                                                                                                 ↓GSH concentration\                               ↑GSH concentration\                       
                                                                                         Finally chosen 20 μΜ dose\     (0.25--2.0 μΜ)\                                                                                                ↑MDA levels,↑Bax, ↓Bcl-2\                         ↓MDA levels, ↓Bax, ↑Bcl-2\                
                                                                                         24 h                           24 h prior to cisplatin                                                                                        ↑ROS generation, ↑Caspace 3\                      ↓ ROS generation, ↓Caspace 3\             
                                                                                                                                                                                                                                       ↑iNOS/TNF-a/IL-1β\                                ↓iNOS/TNF-a/IL-1β\                        
                                                                                                                                                                                                                                       Nuclear fragmentation and cellular condensation   Blunted apoptotic changes\                
                                                                                                                                                                                                                                                                                         Antiapoptotic action (PI3K/Akt pathway)   

  \[[@B38-jcm-09-01284]\]/\   Preclinical study using huMSCs in adult male Wistar rats   2.5% Adenine\                  Icariin\                                            PRE            3, 7, 14 days after treatment               ↑Urine outputm, ↑Urea, ↑Cr\                       ↓Urine output,↓Urea, ↓Cr\                 POS
  China/2017                                                                             Orally\                        huMSCs were pretreated with 100 uM ICA for 1 week                                                              ↑Damage renal tissue, ↑TNF-a\                     ↓Damage renal tissue, ↓TNF-a\             
                                                                                         4 weeks\                                                                                                                                      ↓SOD, ↑MDA, ↑IL-6, ↑IL-10                         ↑SOD, ↓MDA, ↓IL-6, ↓IL-10\                
                                                                                         +4th generation huMSCs                                                                                                                                                                          ↑BMP-7, ↑bFGF                             

  \[[@B17-jcm-09-01284]\]/\   Clinical trial\                                            PN with 20 min cold ischemia   Tadalafil\                                          PRE and POST   Pre-op and at 1,3,8, 24, 48, 72 h post op   ↑NGAL, ↑KIM-1,↑sCr, ↓GFR                          Attenuated all studied parameters         POS
  Israel/2015                 (non-RCT)                                                                                 *[Orally:]{.ul}*20 mg/day\                                                                                                                                                                                 
                                                                                                                        1 day pre-operatively and 2 days postoperatively                                                                                                                                                           

  \[[@B39-jcm-09-01284]\]/\   Clinical trial\                                            RAPN                           Sildenafil\                                         PRE                                                        ↓GFR                                              ↓GFR (No improvement)                     NEUT
  USA/2016                    (RCT)                                                                                     *[Orally]{.ul}*\                                                                                                                                                                                           
                                                                                                                        100 mg prior to RAPN                                                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; Bax, proapoptotic protein; Bcl-2, antiapoptotic gene; bFGF, basic fibroblast growth factor; BMP-7, bone morphogenetic protein-7; GSH, glutathione; HEK, human embryonic kidney cells; huMSCs, human umbilical cord mesenchymal stem cells; iNOS, inducible NOS; IL, interleukin; LY6G, MDA, malondialdehyde; NOX-4, NADPH oxidase 4; PDE5I, phosphodiesterase 5 inhibitor; p-NF-Kb, phosphorylation nuclear factor kappa-light-chain-enhancer of activated B cells; PN, partial nephrectomy; RAPN, Robot assisted partial nephrectomy; RCT, randomized controlled trial; ROS, reactive oxygen species; sCr, serum creatinine; SOD, superoxide dismutase; TNF-a, tumor necrosis factor a; ↓, reduced; ↑, increased.

jcm-09-01284-t002_Table 2

###### 

Animal studies evaluating the potential reno-protective effects of sildenafil.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference\                  Studied Animal                                   AKI Model                                  PDE5I Route                                                Timing         Sample                                                                                                 AKI Renal Effects                                                                                                                                            PDE5I Renal Effects                                                                                    Outcome
  /Country/Year                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  --------------------------- ------------------------------------------------ ------------------------------------------ ---------------------------------------------------------- -------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ ---------
  \[[@B41-jcm-09-01284]\]/\   Male\                                            Cisplatin\                                 Sildenafil\                                                POST           Left nephrectomy 96 h post cisplatin\                                                                  ↑BUN, ↑sCr, ↑Bax/Bcl-2 ratio\                                                                                                                                ↓sCr, ↓Bax/Bcl-2 ratio\                                                                                POS
  South Korea/2009\           Sprague Dawley rats                              Single intraperitoneal injection 5 mg/kg   *Intraperitoneal*\                                                                                                                                                               ↑Caspase 3 expression\                                                                                                                                       ↓Caspase 3 expression\                                                                                 
                                                                                                                          0.4 mg/kg\                                                                                                                                                                       ↑TUNEL positive cells\                                                                                                                                       ↓TUNEL positive cells\                                                                                 
                                                                                                                          Just after the injection of cisplatin                                                                                                                                            Loss of brush border\                                                                                                                                        ↑eNOS and iNOS\                                                                                        
                                                                                                                                                                                                                                                                                                           Vacuolation/Desquamation                                                                                                                                     Significantly attenuated renal changes                                                                 

  \[[@B30-jcm-09-01284]\]/\   Male\                                            IR renal injury model                      Sildenafil\                                                PRE            Depending on the group 0-168 h after reperfusion                                                       ↑BUN, ↑sCr, ↑cGMP\                                                                                                                                           ↓BUN, ↓sCr, ↑↑ cGMP\                                                                                   POS
  Korea/2009\                 Sprague Dawley rats                                                                         *Intraperitoneal*\                                                                                                                                                               ↑Bax/Bcl-2 ratio, ↑Caspase 3 activity\                                                                                                                       ↓Bax/Bcl-2 ratio, ↓Caspase 3 activity\                                                                 
                                                                                                                          0.5 mg/kg\                                                                                                                                                                       ↑TUNEL positive cells\                                                                                                                                       ↓TUNEL positive cells\                                                                                 
                                                                                                                          1 h prior to ischemia                                                                                                                                                            Loss of brush border\                                                                                                                                        ↑↑ ERK activity\                                                                                       
                                                                                                                                                                                                                                                                                                           Vacuolation/Desquamation                                                                                                                                     Attenuated all histological changes                                                                    

  \[[@B42-jcm-09-01284]\]/\   Male Wistar albino rats                          IR renal injury model                      Sildenafil\                                                PRE            Left nephrectomy either at 45 min post occlusion or at 105 min post occlusion and reperfusion injury   ↑MPO enzyme level and activity\                                                                                                                              ↓MPO enzyme level and activity\                                                                        POS
  Turkey/2010                                                                                                             *Orally*\                                                                                                                                                                        ↑TBARS\                                                                                                                                                      ⇔TBARS\                                                                                                
                                                                                                                          60 min pre-operatively                                                                                                                                                           Sclerosis of glomeruli\                                                                                                                                      Attenuated tubular damage\                                                                             
                                                                                                                                                                                                                                                                                                           Enlargement of Bowman space\                                                                                                                                 Preserved normal morphology\                                                                           
                                                                                                                                                                                                                                                                                                           Loss of microvilli/Pyknotic nuclei\                                                                                                                          Significantly decreased neutrophil infiltration\                                                       
                                                                                                                                                                                                                                                                                                           Tubular necrosis/Interstitial edema\                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                           Leucocyte infiltration\                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                           Glomerular and tubular degeneration                                                                                                                                                                                                                                 

  \[[@B43-jcm-09-01284]\]/\   Wistar rats                                      IR renal injury model                      Sildenafil\                                                PRE            At 24 h and 7 days scintigraphy and nephrectomy                                                        Scintigraphy: functional deficit representing ATN No PDE5i: ↑ cellular necrosis Vacuolation\                                                                 Reversed effect to normal split function\                                                              POS
  Brazil/2010                                                                                                             *Orally*\                                                                                                                                                                        Intratubular cast formation                                                                                                                                  PDE5i: just dilatation of tubular lumen\                                                               
                                                                                                                          1 mg/kg\                                                                                                                                                                                                                                                                                                                                      No significant change in histology                                                                     
                                                                                                                          60 min prior to ischemia                                                                                                                                                                                                                                                                                                                                                                                                                             

  \[[@B44-jcm-09-01284]\]/\   Male Wistar rats                                 Cisplatin\                                 Sildenafil\                                                POST           Blood samples and bilateral nephrectomy 5 days post treatment                                          ↓RBF, ↓BP, ↓Body weight ↑Urine output\                                                                                                                       ↑RBF, ↑BP (i.p.)\                                                                                      POS
  Oman/2011                                                                    Single intraperitoneal injection\          *Intraperitoneally*\                                                                                                                                                             ↑BUN, ↑sCr, ↓CrCl\                                                                                                                                           No improvement in b.w. and u.o.\                                                                       
                                                                               5 mg/kg                                    0.4 mg/kg for 5 days\                                                                                                                                                            ↑N-acetyl-β-D-glycosaminidase\                                                                                                                               ↓BUN, ↓sCr, ↑CrCl (i.p.)\                                                                              
                                                                                                                          or\                                                                                                                                                                              ↑TNF-a (plasma and renal)\                                                                                                                                   ↓N-acetyl-β-D-glycosaminidase\                                                                         
                                                                                                                          Sildenafil\                                                                                                                                                                      ↑Renal platinum concentration\                                                                                                                               Minimal improvement in TNF-a\                                                                          
                                                                                                                          *Subcutaneously*\                                                                                                                                                                Acute Tubular Necrosis/Apoptotic cells                                                                                                                       No change in platinum concentration\                                                                   
                                                                                                                          10 mg/kg for 5 days                                                                                                                                                                                                                                                                                                                           Improvement of histological changes                                                                    

  \[[@B45-jcm-09-01284]\]/\   Wistar albino rats                               UUO model\                                 Sildenafil-*orally*-1 mg/day\                              POST           30 days                                                                                                ↑Tubular cell apoptosis\                                                                                                                                     ↓ Tubular cell apoptosis\                                                                              POS
  Turkey/2011                                                                                                             Vardenafil-*orally*-0.5 mg/day\                                                                                                                                                  ↑ eNOS\                                                                                                                                                      ↓ eNOS\                                                                                                
                                                                                                                          Tadalafil-*orally*-10 mg/72 h\                                                                                                                                                   ↑ iNOS\                                                                                                                                                      ↓ iNOS\                                                                                                
                                                                                                                          For 30 days                                                                                                                                                                                                                                                                                                                                   Sildenafil better results                                                                              

  \[[@B46-jcm-09-01284]\]/\   Minipigs                                         IR renal injury model                      Sildenafil\                                                PRE OR SIM     Monitoring of hemodynamics up to 45 min following unclamping                                                                                                                                                                                                        ↓Systemic MAP (especially 1.4 mg/kg)\                                                                  POS
  Spain/2011                                                                                                              *Intravenously*\                                                                                                                                                                                                                                                                                                                              ↑RVF (0.7 mg/kg)                                                                                       
                                                                                                                          0.7 or 1.4 mg/kg 30 min prior to or during warm ischemia                                                                                                                                                                                                                                                                                                                                                                                             

  \[[@B47-jcm-09-01284]\]/\   Male Wistar rats                                 CLP model\                                 Sildenafil\                                                POST           16 h after CLP                                                                                         ↓SOD, ↓GSH, ↑MPO, ↑LPO\                                                                                                                                      ↑SOD, ↑GSH, ↓MPO, ↓LPO\                                                                                POS
  Turkey/2011                                                                                                             Orally\                                                                                                                                                                          ↑Mean inflammation score\                                                                                                                                    ↓Mean inflammation score\                                                                              
                                                                                                                          10 or 20 mg/kg\                                                                                                                                                                  ↑TNF-a                                                                                                                                                       ↓TNF-a                                                                                                 
                                                                                                                          After the procedure                                                                                                                                                                                                                                                                                                                                                                                                                                  

  \[[@B48-jcm-09-01284]\]/\   Female Large White Landrace crossbred pigs       Cardiopulmonary bypass 2.5 h               Sildenafil\                                                SIM            90 min pre-op\                                                                                         ↓CCl, ↑Proteinuria, ↑IL-18\                                                                                                                                  ↑CCl ↓Proteinuria ↓IL-18\                                                                              POS
  United Kingdom                                                                                                          *Intravenously*\                                                          90 min post-op\                                                                                        ↓ NO\                                                                                                                                                        Significantly increased RBF (24 h)\                                                                    
                                                                                                                          10 mg in 50 mL saline 0.9%                                                24 h post-op                                                                                           Pseudodilation of proximal tubules\                                                                                                                          ↑NO\                                                                                                   
                                                                                                                                                                                                                                                                                                           ↑iNOS\                                                                                                                                                       Prevented phenotypic changes in proximal tubular cells\                                                
                                                                                                                                                                                                                                                                                                           ↑ cortical expression endothelin-1\                                                                                                                          ↓cortical expression endothelin-1\                                                                     
                                                                                                                                                                                                                                                                                                           Inflammatory cell infiltration                                                                                                                               Preserved eNOS\                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ↓iNOS\                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ↓ inflammatory cell infiltration                                                                       

  \[[@B49-jcm-09-01284]\]/\   Male\                                            IR renal injury model                      Sildenafil\                                                PRE            Nephrectomy post procedure                                                                             ↑MPO levels\                                                                                                                                                 MPO: no significant improvement\                                                                       POS
  Turkey/2012                 Sprague Dawley rats                                                                         *Orally:* 1 mg/kg\                                                                                                                                                               ↑MDA levels\                                                                                                                                                 ↓MDA (Sdf), ⇔ MDA (Tdf) levels\                                                                        
                                                                                                                          60 min pre-operatively\                                                                                                                                                          ↑iNOS gen, ↑eNOS expression\                                                                                                                                 ↓iNOS gen, ↓eNOS expression\                                                                           
                                                                                                                          Tadalafil\                                                                                                                                                                       ↑ apoptotic cells\                                                                                                                                           ↓apoptotic cell death ( Sdf \> Tdf)\                                                                   
                                                                                                                          *Orally:* 1 mg/kg\                                                                                                                                                               ↑p53 positive cells\                                                                                                                                         ↓p53 positive cells\                                                                                   
                                                                                                                          60 min pre-operatively                                                                                                                                                           Leucocyte migration\                                                                                                                                         All changes were attenuated                                                                            
                                                                                                                                                                                                                                                                                                           Edema/Tubular dilatation                                                                                                                                                                                                                                            

  \[[@B50-jcm-09-01284]\]/\   NO-GC1 KO mice\                                  UUO model                                  Sildenafil\                                                POST           4 weeks post op                                                                                        ↓cGMP\                                                                                                                                                       ↑cGMP\                                                                                                 POS
  Germany/2013\               C57Bl/6Rj                                                                                   *Orally*\                                                                                                                                                                        ↓NO-stimulated guanyle cyclase activity (KO mice)\                                                                                                           ↑NO sensitivity\                                                                                       
                                                                                                                          100 mg/kg\                                                                                                                                                                                                                                                                                                                                    ↓SBP (more efficient in operated group rather than KO group)                                           
                                                                                                                          In the 4th week post op                                                                                                                                                                                                                                                                                                                                                                                                                              

  \[[@B23-jcm-09-01284]\]/\   Female New Zealand white rabbits                 Folic Acid\                                Sildenafil\                                                POST           Blood samples and kidneys were harvested 24 h post treatment                                           ↓mRNA expression COX1 and Tfam\                                                                                                                              ↑mRNA expression COX1 and Tfam\                                                                        POS
  USA/2013\                                                                    Intraperitoneally\                         *Intraperitoneally*\                                                                                                                                                             ↓mtDNA copy number\                                                                                                                                          ↑mtDNA copy number\                                                                                    
                                                                               Single dose\                               24 h after injury\                                                                                                                                                               ↑KIM-1                                                                                                                                                       ↓KIM-1                                                                                                 
                                                                               250 mg/kg                                  0.3 mg/kg/day\                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                          For 6 days                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \[[@B51-jcm-09-01284]\]/\   Sprague Dawley male rats                         Cisplatin\                                 Sildenafil\                                                PRE and POST   96 h after cisplatin injection                                                                         ↑BUN, ↑sCr, ↑MDA, ↑TNF-a\                                                                                                                                    ↓BUN, ↓sCr, ↓MDA, ↓TNF-a\                                                                              POS
  Egypt/2014\                                                                  Intraperitoneally\                         *Intraperitoneally*\                                                                                                                                                             ↑Caspase-3, ↓SOD\                                                                                                                                            ↓Caspase-3, ↑SOD ↑Nitrite/nitrate                                                                      
                                                                               6 mg/kg                                    2 mg/kg\                                                                                                                                                                         ↓Nitrite/nitrate level\                                                                                                                                                                                                                                             
                                                                                                                          1 h before and 24 h after cisplatin injection                                                                                                                                    Acute tubular necrosis                                                                                                                                                                                                                                              

  \[[@B52-jcm-09-01284]\]/\   Adult female Wistar albino rats                  Burn model                                 Sildenafil\                                                POST           24 h after the scald burn                                                                              Renal: ↑MDA, ↓Gpx, ↑VEGF\                                                                                                                                    Renal: ↓MDA, ↑Gpx, ↓VEGF\                                                                              POS
  Turkey/2014\                                                                                                            *Orally*\                                                                                                                                                                        ⇔ Flt-1, ⇔TAC, ⇔OSI, ⇔TOS Serum: ↑MDA, ↓Gpx, ⇔VEGF, ⇔Flt-1, ↓TAC, ⇔OSI, ↑TOS, ⇔Flt-1/VEGF ratio                                                              ⇔Flt-1 (T10), ⇔TAC, ⇔OSI, ⇔TOS(T20)\                                                                   
                                                                                                                          10 or 20 mg/kg just after burn                                                                                                                                                                                                                                                                                                                Serum: ↓MDA, ↑Gpx, ⇔VEGF\                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ⇔Flt-1, ↑TAC, ↓OSI (T10)\                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ↑Flt-1/VEGF ratio (T10) ↓TOS (T10)\                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ↓Histopathological scores (no significant difference in T20)                                           

  \[[@B53-jcm-09-01284]\]/\   Male Wistar rats                                 Gentamicin\                                Sildenafil\                                                PRE            24 h after last gentamycin injection                                                                   ↑Cr, ↑Urea, ↑urinary albumin\                                                                                                                                ↓Cr, ↓Urea, ↓urinary albumin\                                                                          POS
  Egypt/2014\                                                                  Intraperitoneally\                         *Orally*\                                                                                                                                                                        ↑MDA, ↑nitrite/nitrate levels\                                                                                                                               ↓MDA, ↓nitrite/nitrate levels\                                                                         
                                                                               100 mg/kg/day for 6 days                   5 mg/kg/day for 6 days\                                                                                                                                                          ↓CAT (renal), ↓SOD, ↑iNOS, ↓eNOS\                                                                                                                            ↑CAT (renal), ↑SOD\                                                                                    
                                                                                                                          1 h before gentamycin                                                                                                                                                            Degeneration and necrobiosis in epithelial cells                                                                                                             ↓iNOS, ↑eNOS\                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Reversed histological alterations                                                                      

  \[[@B54-jcm-09-01284]\]/\   Male wild-type (WT) littermates or PKG Tg mice   UUO model\                                 Sildenafil\                                                POST           14 days                                                                                                ↓Renal PKG activity\                                                                                                                                         ↑Renal PKG activity\                                                                                   POS
  USA/2014\                                                                                                               *Subcutaneously*\                                                                                                                                                                Increase (↑) at Ang II, Collagen type I, III mRNA, α-SMA, E-cadherin, TNF-a, TGF-β1, pSmad2, ICAM-1\                                                         Decrease (↓) at Ang II, Collagen type I, III mRNA, α-SMA, E-cadherin, TNF-a, TGF-β1, pSmad2, ICAM-1\   
                                                                                                                          12 mg/kg twice daily for 14 days                                                                                                                                                 ↑Macrophage infiltration                                                                                                                                     ↓Macrophage infiltration                                                                               

  \[[@B55-jcm-09-01284]\]/\   New Zealand white rabbits                        CIN model                                  Sildenafil\                                                PRE and POST   1/2/24/48\                                                                                             No changes in kidney to body weight ratio\                                                                                                                   No significant changes in kidney to body weight ratio\                                                 POS
  Brazil/2014\                                                                                                            *Orally*\                                                                 h                                                                                                      ↑sCr\                                                                                                                                                        ↓↓sCr (continuous)\                                                                                    
                                                                                                                          6 mg/kg before CM\                                                                                                                                                               ↓Na, ↑K\                                                                                                                                                     ↑Na, ↓K\                                                                                               
                                                                                                                          or\                                                                                                                                                                              Multifocal tubular necrosis\                                                                                                                                 Continuous treatment blunted all changes                                                               
                                                                                                                          6 mg/kg before CM and 8 hourly for 48 h                                                                                                                                          Tubular degeneration\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                           Luminal protein casts                                                                                                                                                                                                                                               

  \[[@B56-jcm-09-01284]\]/\   Male Sprague-Dawley rats                         IR renal injury model                      Sildenafil\                                                PRE            Blood + urine samples (basal, at 2, 24, 48 h and 7 days)\                                              ↑sCr, ↑BUN, ↓Bcl-2\                                                                                                                                          No improvement in BUN/sCr, ↑Bcl-2\                                                                     POS
  Egypt/2015\                                                                                                             *Orally*\                                                                 +\                                                                                                     ↓Nrf2/HO-1/NQO-1 (genes)\                                                                                                                                    ↑Nrf2/HO-1/NQO-1 (genes)\                                                                              
                                                                                                                          (1 mg/kg)\                                                                Kidney tissue                                                                                          ↑ Proinflammatory cytokine genes (TNF-a, ICAM-1, IL-β)\                                                                                                      ↓ Proinflamamtory cytokine genes (TNF-a, ICAM-1, IL-β)\                                                
                                                                                                                          60 min before anesthesia                                                                                                                                                         ↓Nrf 2 protein expression\                                                                                                                                   ↑ Nrf 2 protein expression\                                                                            
                                                                                                                                                                                                                                                                                                           Acute tubular necrosis, detachment of epithelial cells from basement membrane, intracellular cast formation, loss of brush border, neutrophil infiltration   Improved histological features of renal injury (mild tubular necrosis)                                 

  \[[@B57-jcm-09-01284]\]/\   Male Wistar rats                                 CIN model                                  Sildenafil\                                                PRE and POST   48 h after CM administration                                                                           ↑BUN, ↑sCr, ↑urine protein\                                                                                                                                  ↓BUN, ↓sCr, ↓urine protein\                                                                            POS
  Brazil/2016\                                                                                                            *Orally*\                                                                                                                                                                        ↓GFR, ↓RPF, ↑RVR\                                                                                                                                            ↑GFR, ↑RPF, ↓RVR\                                                                                      
                                                                                                                          50 mg/kg/d\                                                                                                                                                                      ↑superoxide anions production\                                                                                                                               ⇔superoxide anions production\                                                                         
                                                                                                                          7 days (started 5 days before CM)                                                                                                                                                ↑H~2~O~2~ production\                                                                                                                                        ↓ H~2~O~2~ production\                                                                                 
                                                                                                                                                                                                                                                                                                           ↑peroxynitrite and hydroxyl production\                                                                                                                      ↓peroxynitriteand hydroxyl production\                                                                 
                                                                                                                                                                                                                                                                                                           ⇔ NO\                                                                                                                                                        ⇔ NO\                                                                                                  
                                                                                                                                                                                                                                                                                                           Reduced body weight\                                                                                                                                         No effect of PDE5 on histological changes                                                              
                                                                                                                                                                                                                                                                                                           Renal hypertrophy                                                                                                                                                                                                                                                   

  \[[@B58-jcm-09-01284]\]/\   Male Wistar albino rats                          IR renal injury model                      Sildenafil\                                                PRE            Blood/kidney tissue samples 24 h after reperfusion                                                     ↓CrCl, ↑ BUN, ↑Uric acid, ↑FeNa\                                                                                                                             ↑CrCl, ↓BUN, ↓Uric acid\                                                                               POS
  Egypt/2016                                                                                                              *Intraperitoneally*\                                                                                                                                                             ↑Plasma potassium\                                                                                                                                           ↓FeNa\                                                                                                 
                                                                                                                          (0.5 + 1.0 mg/kg)\                                                                                                                                                               ↓GSH levels,↑TBARS, ↑SAG levels\                                                                                                                             ↓Plasma potassium ↑GSH levels, ↓TBARS ↓ SAG levels\                                                    
                                                                                                                          1 h before ischemia                                                                                                                                                              Glomerular damage, detachment of basement membrane, loss of brush border, tubular dilation, atroprhy, neutrophil accumulation                                ↓Renal tissue damage                                                                                   

  \[[@B59-jcm-09-01284]\]/\   Female\                                          CIN model                                  Sildenafil\                                                PRE            48 h after CM administration                                                                           ↑HIF-2a (serum and tissue)\                                                                                                                                  ↓HIF-2a (serum and tissue) ↓ sCr\                                                                      POS
  Turkey/2018                 Wistar albino rats                                                                          *Orally*\                                                                                                                                                                        ↑ BUN, ↑Cr (serum and urine)\                                                                                                                                Sildenafil improved all histological changes                                                           
                                                                                                                          50 mg/kg 48 h prior to CM                                                                                                                                                        Hemorrhage, shedding of brush border, tubular vacuolization, degeneration, inflammatory cell infiltration, intratubulat cast obstruction                                                                                                                            

  \[[@B60-jcm-09-01284]\]/\   Male albino rats                                 Cisplatin\                                 Combination\                                               PRE OR POST    Day 17                                                                                                 ↑sCr, ↓HO-1, ↓GSH\                                                                                                                                           All changes improved with sildenafil and gemfibrozil especially in the group given after cisplatin     POS
  Egypt/2018                                                                   5 mg/kg\                                   Sildenafil, *Orally*\                                                                                                                                                            ↓eNOS, ↓TNF-a\                                                                                                                                                                                                                                                      
                                                                               Single dose intraperitoneally              40 mg/kg\                                                                                                                                                                        ↑Tubular injury/tubular necrosis                                                                                                                                                                                                                                    
                                                                                                                          Gemfibrozil-*Orally*--\                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                          100 mg/kg\                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                          14 days prior or after                                                                                                                                                                                                                                                                                                                                                                                                                               

  \[[@B61-jcm-09-01284]\]/\   Mongrel dogs (aged 2-3 years)                    IR renal injury model                      Sildenafil\                                                PRE OR SIM     Prior and at the end of the experiment\                                                                ↑sCr, ↑BUN, ↓GFR\                                                                                                                                            ↓sCr, ↓BUN, ↑GFR\                                                                                      POS
  Egypt/2019                                                                                                              *Orally*\                                                                 (Day 1,3,7,14)                                                                                         ↑caspase 3, ↑Nrf2\                                                                                                                                           ↓caspase 3, ↑↑Nrf2\                                                                                    
                                                                                                                          1 mg/kg 1 h prior to operation\                                                                                                                                                  ↑TNF-a, ↑ IL-1Β, ↑ICAM -1\                                                                                                                                   ↓TNF-a, ↓IL-1Β, ↓ICAM -1\                                                                              
                                                                                                                          or\                                                                                                                                                                              ↓eNOS\                                                                                                                                                       ↑eNOS\                                                                                                 
                                                                                                                          *In the perfusion fluid*\                                                                                                                                                        Renal degeneration\                                                                                                                                          Significantly improved all histological changes                                                        
                                                                                                                          0.5 mg/kg during the operation                                                                                                                                                   Cortical and medullary interstitial fibrosis                                                                                                                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; Ang II, angiotensin II; Bax, proapoptotic protein; Bcl-2, antiapoptotic gene; BP, blood pressure; BUN, blood urea nitrogen; Ca^2+^, calcium; CAT, catalase; cGMP, cyclic guanosine monophosphate; CIN, contrast induced nephropathy; CLP, caecal ligation and puncture; COX, cyclo-oxygenase CrCl, creatinine clearance, eNOS, endothelial NOS, FeNa, fractional excretion of sodium, GFR, glomerular filtration rate; GPx, glutathione peroxidase; GSH, glutathione; HIF-2a, heterodimeric nuclear transcription factor-2 alpha; HO-1, heme oxygenase 1; IR, ischemia reperfusion; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; iNOS, inducible NOS; K, potassium; KIM-1, kidney injury molecule-1; LPO, lipid peroxidation; MAP, mean arterial pressure; MDA, malondialdehyde; MPO, myeloperoxidase; Na, sodium; NO, nitric oxide; NRF2, nuclear erythroid related factor 2; OSI, oxidative stress index; P, phosphorus; PDE5I, phosphodiesterase 5 inhibitor; PKG, protein kinase G; pSmad2, antibody; RBF, renal blood flow; RPF, renal plasma flow; RRI, renal resistive index; RVF, renal vascular flow; RVR, renal vascular resistance; SAG, superoxide anion generation; sCr, serum creatinine; sFlt1, soluble fms-like tyrosine kinase-1; SOD, superoxide dismutase; SBP, systolic blood pressure; TAC, total antioxidant capacity; Tfam, mitochondrial transcription factor; TGF-β1, transforming growth factor beta 1; TBARS, thiobarbituric acid reactive substances; TNF-a, tumor necrosis factor a; TOS, total oxidant status; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; UUO, unilateral ureteral obstruction; VEGF, vascular endothelia growth factor; ↓, reduced; ↑, increased ⇔, no change.
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###### 

Animal studies evaluating the potential reno-protective effects of tadalafil.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                           Studied Animal              AKI Model               PDE5I Route                                         Timing         Sample                                                                         AKI Renal Effects                                                                                                PDE5I Renal Effects                                                              Outcome
  Country/Year                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------------------- --------------------------- ----------------------- --------------------------------------------------- -------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ---------
  \[[@B62-jcm-09-01284]\]/\             New Zealand rabbits         UUO model\              Tadalafil\                                          PRE            4th hour and 1^st^ and 3rd day                                                 ↑Resistivity index\                                                                                              ↓Resistivity index\                                                              POS
  Turkey/2019                                                                               *Orally*\                                                                                                                                         ↑Pulsatility index                                                                                               ↓Pulsatility index\                                                              
                                                                                            10 mg/72 h for 30 days prior to obstruction                                                                                                                                                                                                                        In the non-obstructed kidney reduced resistivity index at 4th hour then normal   

  \[[@B63-jcm-09-01284]\]/\             Male\                       IR renal injury model   Tadalafil\                                          PRE            At 45 min post occlusion or at 105 min post occlusion and reperfusion injury   Sclerosis of glomeruli\                                                                                          Attenuated histological changes and decreased neutrophil infiltration            POS
  Turkey/2011                           Sprague Dawley rats                                 *Orally*\                                                                                                                                         Enlargement of Bowman space\                                                                                                                                                                      
                                                                                            1 mg/kg\                                                                                                                                          Loss of microvilli/Tubular necrosis Interstitial edema/Leucocyte infiltration\                                                                                                                    
                                                                                            60 min pre-operatively                                                                                                                            Hyaline degeneration                                                                                                                                                                              

  \[[@B45-jcm-09-01284]\]/\             Wistar albino rats          UUO model\              Sildenafil-*orally*-1 mg/day\                       POST           30 days                                                                        ↑Tubular cell apoptosis\                                                                                         ↓Tubular cell apoptosis\                                                         POS
  Turkey/2011                                                                               Vardenafil-*orally*-0.5 mg/day\                                                                                                                   ↑eNOS\                                                                                                           ↓eNOS\                                                                           
                                                                                            Tadalafil-*orally*-10 mg/72 h\                                                                                                                    ↑iNOS\                                                                                                           ↓iNOS\                                                                           
                                                                                            For 30 days                                                                                                                                                                                                                                                        Sildenafil better results                                                        

  \[[@B64-jcm-09-01284]\]/\             Male Wistar albino rats     IR renal injury model   Tadalafil\                                          PRE            Left nephrectomy at 120 min post-operatively                                   ↑Total oxidant status\                                                                                           ↑ Total antioxidant status\                                                      POS
  Turkey/2011                                                                               *Orally*\                                                                                                                                         Tubular necrosis/Vacuolization Congestion/Mononuclear cell infiltration                                          Reduced all injuries to the renal tissue.                                        
                                                                                            10 mg/kg\                                                                                                                                                                                                                                                                                                                                           
                                                                                            60 min pre-operatively                                                                                                                                                                                                                                                                                                                              

  \[[@B65-jcm-09-01284]\]/\             Adult female pigs           IR renal injury model   Tadalafil\                                          PRE            Induction\                                                                     ↑Creatinine after nephrectomy\                                                                                   ↓Creatinine after nephrectomy\                                                   POS
  USA/2012\                                                                                 40 mg\                                                             and\                                                                           ↑↑ Creatinine Day 1 post ischemia                                                                                No significant change in creatinine Day 1 post ischemia                          
                                                                                            Two doses (12 h before and just prior to surgery)                  Days 1, 3, 7 post occlusion                                                                                                                                                                                                                                                      

  \[[@B49-jcm-09-01284]\]/\             Male\                       IR renal injury model   Sildenafil\                                         PRE            Nephrectomy post procedure                                                     ↑ MPO levels\                                                                                                    MPO: no significant improvement\                                                 POS
  Turkey/2012                           Sprague Dawley rats                                 *Orally:* 1 mg/kg\                                                                                                                                ↑MDA levels\                                                                                                     ↓MDA (Sdf), ⇔MDA (Tdf) levels\                                                   
                                                                                            60 min pre-operatively\                                                                                                                           ↑iNOS gen, ↑eNOS expression\                                                                                     ↓iNOS gen, ↓eNOS expression\                                                     
                                                                                            Tadalafil\                                                                                                                                        ↑apoptotic cells\                                                                                                ↓apoptotic cell death (Sdf \> Tdf)\                                              
                                                                                            *Orally:* 1 mg/kg\                                                                                                                                ↑p53 positive cells\                                                                                             ↓p53 positive cells\                                                             
                                                                                            60 min pre-operatively                                                                                                                            Leucocyte migration\                                                                                             All changes were attenuated                                                      
                                                                                                                                                                                                                                              Edema/Tubular dilatation                                                                                                                                                                          

  \[[@B66-jcm-09-01284]\]/\             Male\                       IR renal injury model   Tadalafil\                                          PRE            30/60 min after nephrectomy\                                                   ↑V, ↑U~Na~V, ↑FeNa, ↓GFR, ⇔RPF, ↑NGAL, ↑KIM-1\                                                                   ↓V, ↓U~Na~V, ↓FeNa, ↑GFR, ↑RPF, ↓NGAL, ↓KIM-1\                                   POS
  Israel/2013                           Sprague Dawley rats                                 *Orally*\                                                          60/120/180/240\                                                                Tubular dilatation/Loss of brush border\                                                                         Blunted all changes                                                              
                                                                                            10 mg/kg\                                                          min after clamping                                                             Necrosis and cast formation                                                                                                                                                                       
                                                                                            24-hr prior to ischemia                                                                                                                                                                                                                                                                                                                             

  \[[@B67-jcm-09-01284]\]/\             Male Wistar rats            Sepsis model            Tadalafil\                                          PRE and POST   Nephrectomy and samples at: 8 days post treatment and 6 weeks post treatment   ↑Systolic and diastolic BP, ↑NO\                                                                                 ↓Systolic and diastolic BP, ↓NO, ↓BUN, ↓sCr, ↓MDA levels, ↑SOD\                  POS
  China/2014                                                                                *Orally*\                                                                                                                                         ↑BUN, ↑sCr, ↑MDA levels ↓SOD, ↑TGF-β                                                                             ↑IL-10, ↓TNF-a, ↓IL-1β, ↓TGF-β\                                                  
                                                                                            10 mg/kg\                                                                                                                                                                                                                                                          ↓RANTES, ↓MIP-1β, ↓MCP-1                                                         
                                                                                            24 h prior to procedure for 28 days                                                                                                                                                                                                                                                                                                                 

  \[[@B68-jcm-09-01284]\]/\             Female Wistar albino rats   IR renal injury model   Tadalafil\                                          PRE            Cardiac blood samples and nephrectomy after reperfusion injury                 No significant difference\                                                                                       in IMA/NO/MDA levels\                                                            POS
  Turkey/2015                                                                               Orally\                                                                                                                                           Severe tubular dilatation degeneration and necrosis/Enlargement of Bowman capsule                                Blunted all changes                                                              
                                                                                            10 mg/kg\                                                                                                                                                                                                                                                                                                                                           
                                                                                            24 h prior to procedure                                                                                                                                                                                                                                                                                                                             

  \[[@B69-jcm-09-01284]\]/Turkey/2015   Wistar albino rats          IR renal injury model   Tadalafil\                                          PRE            Blood samples and nephrectomy following 60 min of reperfusion injury           ↑MDA levels (serum/renal)\                                                                                       ⇔MDA (renal), ↓MDA (serum)\                                                      POS
                                                                                            *Intraperitoneally*\                                                                                                                              ↓TAC levels (serum/renal)\                                                                                       ⇔TAC (renal), ↑TAC (serum)\                                                      
                                                                                            10 mg/kg\                                                                                                                                         ↑APAF-1, ↑iNOS, ↑eNOS\                                                                                           ↓APAF-1, ↓iNOS, ↓eNOS\                                                           
                                                                                            Immediately prior to procedure                                                                                                                    Loss of nucleus/Cellular edema\                                                                                  Damage was significantly less after tadalafil treatment                          
                                                                                                                                                                                                                                              Vacuolization/Brush border loss\                                                                                                                                                                  
                                                                                                                                                                                                                                              Tubular dilatation/edema\                                                                                                                                                                         
                                                                                                                                                                                                                                              Interstitial congestion                                                                                                                                                                           

  \[[@B35-jcm-09-01284]\]/Turkey/2015   Female Wistar albino rats   CIN model               Tadalafil\                                          POST           48 h after CM administration                                                   Significant weight loss after dehydration\                                                                       Significant weight loss after dehydration\                                       POS
                                                                                            *Orally*\                                                                                                                                         ↑Serum cystatin C\                                                                                               ↓Serum cystatin C\                                                               
                                                                                            10 mg/kg\                                                                                                                                         ↑BUN, ↑sCr, ↑MDA\                                                                                                ↓BUN, ↓sCr, ↓MDA\                                                                
                                                                                            immediately after contrast                                                                                                                        Medullary congestion                                                                                             Similar histological findings                                                    

  \[[@B29-jcm-09-01284]\]/\             Adult male albino rats      IR renal injury model   Tadalafil\                                          PRE            Blood/kidney tissue samples 6 h after reperfusion                              ↑sCr, ↑BUΝ, ↑MDA levels\                                                                                         ↓sCr, ↓BUΝ, ↓MDA levels\                                                         POS
  Egypt/2016                                                                                *Orally*\                                                                                                                                         ↓SOD activity, ↑MPO activity\                                                                                    ↑SOD activity, ↓MPO activity\                                                    
                                                                                            (5 mg/kg)\                                                                                                                                        ↑ICAM-1, ↑TNF-a, ↑IL-1β\                                                                                         ↓ICAM-1, ↓TNF-a, ↓IL-1β\                                                         
                                                                                            Pre-treatment\                                                                                                                                    ↑Caspase-3 activity\                                                                                             ↓Caspase-3 activity\                                                             
                                                                                                                                                                                                                                              Congestion and interstitial hemorrhage, proximal and tubular necrosis                                            Dilated proximal, distal, and collecting tubules and interstitial connection     

  \[[@B70-jcm-09-01284]\]/\             Male Wistar rats            Cisplatin\              Tadalafil\                                          PRE            Blood samples and renal tissue obtained 3 days post cisplatin                  ↓Na/K/HCO~3/~Ca^2+^/P\                                                                                           Significant attenuation of all histological and biochemical alterations          POS
  Nigeria/2016                                                      Intraperitoneal\        *Orally:* 2 or 5 mg/kg for 7 days pretreatment                                                                                                    ↑BUN, ↑sCr, ↑MDA/GPx\                                                                                                                                                                             
                                                                    5 mg/kg                                                                                                                                                                   ↓GSH/SOD/CAT (renal)                                                                                                                                                                              

  \[[@B71-jcm-09-01284]\]/\             Male albino Wistar rats     CLP model               Tadalafil\                                          POST           Left nephrectomy\                                                              ↓CAT, ↓SOD, ↑IL-6, ↑sCr, ↑MPO, ↑MDA, ↑Cystatin C\                                                                ↑CAT, ↑SOD, ↓IL-6, ↓sCr, ↓MPO, ↓MDA, ↓Cystatin C\                                POS
  Israel/2017                                                                               *Orally*\                                                          +\                                                                             ↑Mac387 antibody\                                                                                                ↓Mac387 antibody\                                                                
                                                                                            5 or 10 mg/kg\                                                     Blood samples\                                                                 ↑Tubular injury, glomerulus deformities\                                                                         ↓Tubular injury, glomerulus deformities\                                         
                                                                                            End of the procedure                                               16 h postoperatively                                                           ↑Inflammatory cell infiltration                                                                                  ↓Inflammatory cell infiltration                                                  

  \[[@B72-jcm-09-01284]\]/\             Male Wistar rats            IR renal injury model   Tadalafil\                                          PRE            After nephrectomy                                                              Interstitial Leucocyte accumulation                                                                              Successful reversal by tadalafil                                                 POS
  Brazil/2017                                                                               *Orally*\                                                                                                                                                                                                                                                                                                                                           
                                                                                            10 mg/kg\                                                                                                                                                                                                                                                                                                                                           
                                                                                            1 h pre-procedure                                                                                                                                                                                                                                                                                                                                   

  \[[@B73-jcm-09-01284]\]/\             Male Wistar rats            IR renal injury model   Tadalafil\                                          PRE            Fluorescence imaging (ICG)\                                                    ↓ICG signal, ↑TNF-a, ↑IL-1β\                                                                                     ↑ICG signal, ↓TNF-a, ↓IL-1β\                                                     POS
  Brazil/2017                                                                               *Orally:* 10 mg/kg\                                                Blood samples                                                                  ↑IL-6 ↑BUN, ↑sCr, ↑CRP                                                                                           ↓IL-6 ↓BUN, ↓sCr, ↓CRP                                                           
                                                                                            1 h before ischemia                                                                                                                                                                                                                                                                                                                                 

  \[[@B74-jcm-09-01284]\]/\             Male Sprague Dawley rats    UUO model               Tadalafil\                                          \-\--          15 days post ligation                                                          ↑aSMA, ↑TGF-β\                                                                                                   ↓aSMA, ↓TGF-β\                                                                   POS
  Turkey/2019                                                                               *Orally*\                                                                                                                                         Partial: inflammatory cell infiltration/severe epithelial atrophy/edema of epithelial cells/vacuolation\         \                                                                                
                                                                                            10 mg/72 h                                                                                                                                        Complete: macrophage infiltration/hemorrhage/irregular dark nuclei/thinner epithelium/denuded epithelial cells   \                                                                                
                                                                                                                                                                                                                                                                                                                                                               Attenuation of all changes with tadalafil                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: AKI, acute kidney injury; APAF-1, apoptotic protease activating factor 1; aSMA, α-smooth muscle actin; BUN, blood urea nitrogen; Ca^2+^, calcium; CAT, catalase; CIN, contrast induced nephropathy; CLP, caecal ligation and puncture; CRP, c-reactive protein; eNOS, endothelial NOS; FeNa, fractional excretion of sodium; GFR, glomerular filtration rate; GPx, glutathione peroxidase; GSH, glutathione; HCO~3~^−^, bicarbonate; IR, ischemia/reperfusion; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; ICG, indocyanine green; IMA, ischemia modified albumin; iNOS, inducible NOS; K, potassium; KIM-1, kidney injury molecule-1; Mac387, Macrophage antibody; MCP-1, monocyte chemoattractant protein 1; MDA, malondialdehyde; MIP-1β, macrophage inflammatory protein-1β; MPO, myeloperoxidase; Na, sodium; NGAL, neutrophil gelatinase-associated lipocalin; NO, nitric oxide; P, phosphorus; PDE5I, phosphodiesterase 5 inhibitor; RANTES, Regulated upon Activation Normal T-cell Expressed, and Secreted; RPF, renal plasma flow; sCr, serum creatinine; Sdf, sildenafil; SOD, superoxide dismutase; TAC, total antioxidant capacity; Tdf, tadalafil; TGF-β1, transforming growth factor beta 1; TNF-a, tumor necrosis factor a; UNaV, urine sodium volume; UUO, unilateral ureteral obstruction; V, urine volume; ↓, reduced; ↑, increased ⇔, no change.

jcm-09-01284-t004_Table 4

###### 

Animal studies evaluating the potential reno-protective effects of icariin.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                 Studied Animal       AKI Model          PDE5I Route                                   Timing         Sample                           AKI Renal Effects                                                                                                                            PDE5I Renal Effects                                    Outcome
  Country/Year                                                                                                                                                                                                                                                                                                                                                          
  --------------------------- -------------------- ------------------ --------------------------------------------- -------------- -------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------
  \[[@B75-jcm-09-01284]\]/\   Male BALB/c mice     Cisplatin\         Icariin\                                      PRE            At 6 days                        ↑BUN, ↑sCr, ↑MDA\                                                                                                                            ↓BUN, ↓sCr,↓MDA\                                       POS
  China/2015                                       15 mg/kg\          *Orally*\                                                                                     ↓GSH concentration, ↓Catalase\                                                                                                               ↑GSH concentration, ↑Catalase\                         
                                                   Intraperitoneal\   30 or 60 mg/kg/day\                                                                           ↓SOD activity, ↑TNF-a, ↑NF-Kb\                                                                                                               ↑SOD activity, ↓TNF-a, ↓NF-kB\                         
                                                                      For 6 days                                                                                    ↑TUNEL positive cells\                                                                                                                       ↓TUNEL positive cells\                                 
                                                                                                                                                                    ↑Caspase-3, ↓Bcl-2\                                                                                                                          ↓Caspase-3, ↑Bcl-2\                                    
                                                                                                                                                                    Tubular congestion/edema\                                                                                                                    Partial improvement of the features (dose dependent)   
                                                                                                                                                                    Loss of brush border/Tubular cell flattening and necrosis/nuclear pyknosis\                                                                                                                         
                                                                                                                                                                    Severe invasion of inflammatory cells                                                                                                                                                               

  \[[@B18-jcm-09-01284]\]/\   Male C57BL/6N mice   CLP model          Icariin\                                      PRE            Observed for 5 days              ↑BUN, ↑sCr, ↑MDA levels\                                                                                                                     ↓BUN, ↓sCr, ↓MDA levels\                               POS
  China/2018                                                          *Orally*\                                                                                     ↑IL-1β/IL-6/TNF-a ↑ NF-κB\                                                                                                                   ↓IL-1β/IL-6/TNF-a, ↓ NF-κB\                            
                                                                      30 or 60 mg/kg\                                                                               ↓ GSH concentration\                                                                                                                         ↑GSH concentration\                                    
                                                                      3 days prior to surgery                                                                       ↓Catalase, ↓SOD activity\                                                                                                                    ↑Catalase, ↑SOD activity\                              
                                                                                                                                                                    ↑TUNEL +ve cells\                                                                                                                            ↓TUNEL +ve cells (60\>30)\                             
                                                                                                                                                                    ↑Renal vascular permeability\                                                                                                                ↓Renal vascular permeability\                          
                                                                                                                                                                    ↑Bax,↓Bcl-2, ↑Caspase 3\                                                                                                                     ↓Bax, ↑Bcl-2, ↓Caspase 3\                              
                                                                                                                                                                    Extensive tubular necrosis/Loss of brush border                                                                                              ↑Survival (both doses)\                                
                                                                                                                                                                                                                                                                                                                 Improvement in all histological features               

  \[[@B76-jcm-09-01284]\]/\   Adult C57BL/6J       UUO model          Icariin\                                      PRE and POST   3, 7, or 14 days post ligation   ↑TGF-β, ↑α-SMA ↑fibronectin\                                                                                                                 ↓TGF-β, ↓α-SMA, ↓fibronectin\                          POS
  Taiwan/2019                                                         *Orally*\                                                                                     ↑NOX-4, ↓E-cadherin, ↓SOD-1\                                                                                                                 ↓NOX-4,↑E-cadherin, ↑SOD-1\                            
                                                                      20 mg/kg/day\                                                                                 ↓Catalase, ↑CTGF, ↑Ly6G\                                                                                                                     ↑Catalase, ↓CTGF, ↓Ly6G\                               
                                                                      For 3 days prior and 3, 7, or 14 days after                                                   ↑F4/80, ↑phosphorylation IL-1β\                                                                                                              ↓F4/80, ↓phosphorylation IL-1β\                        
                                                                                                                                                                    ↑Phosphorylation COX-2/NF-κΒ-65\                                                                                                             ↓Phosphorylation COX-2/NF-κΒ-65\                       
                                                                                                                                                                    Tubular dilatation/interstitial cell proliferation/inflammatory cell infiltration/tuft to capsule glomerular adhesions/collagen deposition   Non-significant moderate reversal by icariin           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; Bcl-2, antiapoptotic gene; BUN, blood urea nitrogen; CLP, caecal ligation and puncture; COX, cyclo-oxygenase; CTGF, connective tissue growth factor; F4/80, macrophage marker; GSH, glutathione; IL, interleukin; LY6G, neutrophil marker; MDA, malondialdehyde; NF-κB, nuclear factor kappa-like chain-enhancer of activated B cells; NOX-4, NADPH oxidase 4; PDE5I, phosphodiesterase 5 inhibitor; sCr, serum creatinine; SOD, superoxide dismutase; TGF-β1, transforming growth factor beta 1; TNF-a, tumor necrosis factor a; TUNEL, Terminal deoxynucleotidyl transferase dUTP nick end labeling; UUO, unilateral ureteral obstruction; ↓, reduced; ↑, increased.

jcm-09-01284-t005_Table 5

###### 

Animal studies evaluating the potential reno-protective effects of vardenafil.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                 Studied Animal       AKI Model                PDE5I Route                                    Timing        Sample                                                  AKI Renal Effects          PDE5I Renal Effects                                                           Outcome
  Country/Year                                                                                                                                                                                                                                                                                            
  --------------------------- -------------------- ------------------------ ---------------------------------------------- ------------- ------------------------------------------------------- -------------------------- ----------------------------------------------------------------------------- ---------
  \[[@B45-jcm-09-01284]\]/\   Wistar albino rats   UUO model\               Sildenafil-*orally*-1 mg/day\                  POST          30 days                                                 ↑Tubular cell apoptosis\   ↓Tubular cell apoptosis\                                                      POS
  Turkey/2011                                                               Vardenafil-*orally*-0.5 mg/day\                                                                                      ↑eNOS\                     ↓ eNOS\                                                                       
                                                                            Tadalafil-*orally*-10 mg/72 h\                                                                                       ↑ iNOS                     ↓iNOS\                                                                        
                                                                            For 30 days                                                                                                                                     Sildenafil better results                                                     

  \[[@B77-jcm-09-01284]\]/\   Male Wistar rats     IR renal injury model\   Vardenafil\                                    PRE or POST   Blood samples and right nephrectomy 4 h post ischemia   Edema\                     ↓sCr (0.2, 2, 20 μg/kg)\                                                      POS
  Greece/2013                                                               *Intravenously*\                                                                                                     Loss of brush border\      No change when given post-ischemia\                                           
                                                                            0.02, 0.2, 2, 20 μg/kg\                                                                                              Nuclear condensation       ↓FENa, ↑Renal uptake of tracer\                                               
                                                                            1 h pre-operatively\                                                                                                                            ↑cGMP, ↑ERK 1/2 phosphorylation\                                              
                                                                            or 2μg/kg 45 min post occlusion                                                                                                                 Renoprotection (in scintigraphy)\                                             
                                                                                                                                                                                                                            Significant improvement in all histo-logical changes irrespectively of dose   

  \[[@B78-jcm-09-01284]\]/\   Male Wistar rats     IR renal injury model    Vardenafil\                                    PRE           Left nephrectomy\                                       ↑Cleaved caspase-3 ↑sCr\   ↓ Cleaved caspase-3\                                                          POS
  Brazil/2015                                                               *Solution in a probe* (1 mg/mL in 10 mg/kg)\                 Cytophotometry\                                         ↑Vacuolar degeneration\    ↓ Vacuolar degeneration                                                       
                                                                            1 h prior the ligation                                       24 h after reperfusion                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; cGMP, cyclic guanosine monophosphate; eNOS, endothelial NOS; ERK, extracellular signal-regulated kinase; FeNa, fractional excretion of sodium; IR, ischemia/reperfusion; iNOS, inducible NOS; PDE5I, phosphodiesterase 5 inhibitor; sCr, serum creatinine; UUO, unilateral ureteral obstruction; ↓, reduced; ↑, increased.

jcm-09-01284-t006_Table 6

###### 

Animal studies evaluating the potential reno-protective effects of zaprinast and udenafil.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference/\                           Studied Animal               AKI Model               PDE5I Route               Timing   Sample                                                             AKI Renal Effects   PDE5I Renal Effects                                                                                                         Outcome
  Country/Year                                                                                                                                                                                                                                                                                                                                     
  ------------------------------------- ---------------------------- ----------------------- ------------------------- -------- ------------------------------------------------------------------ ------------------- --------------------------------------------------------------------------------------------------------------------------- ---------
  \[[@B79-jcm-09-01284]\]/\             Male Sprague-Dawley rats     IR renal injury model   Zaprinast\                POST     During clamping, PDE5i infusion, up to 6 days following ischemia   ↑sCr, ↓GFR          ↓sCr, ↑GFR, ↓Low MAP\                                                                                                       POS
  USA/1995                                                                                   *Intravenously*\                                                                                                          ↑U~Na~V, ↑Urinary cGMP\                                                                                                     
                                                                                             0.03 and 0.3 mg/kg/min\                                                                                                   ↑Cortical and medullary blood flow                                                                                          
                                                                                             24 h after ischemia                                                                                                                                                                                                                                   

  \[[@B40-jcm-09-01284]\]/\             Female Sprague-Dawley rats   IR renal injury model   Zaprinast\                PRE      24 h post operatively\                                                                 No statistically significant differrences in either BUN levels or sCr levels or histologic scores or TUNEL positive cells   NEUT
  USA/2013                                                                                   *Intraperitoneally*\               blood samples and left nephrectomy                                                                                                                                                                                 
                                                                                             10 mg/kg or 20 mg/kg\                                                                                                                                                                                                                                 
                                                                                             Single dose\                                                                                                                                                                                                                                          
                                                                                             30 min pre-operatively                                                                                                                                                                                                                                

  \[[@B80-jcm-09-01284]\]/\             6-8-week-old mice            UUO model               Zaprinast,\               POST     After 7 days                                                       ↑cGMP, ↑sCr         ↑↑cGMP, ↑MMP9, ↑TGF-β\                                                                                                      POS
  Germany/2017                                                                               *Intraperitoneally*\                                                                                                      ⇔sCr, ↓Collagen                                                                                                             
                                                                                             10 mg/kg/day for 7 days                                                                                                                                                                                                                               

  \[[@B21-jcm-09-01284]\]/Turkey/2017   Female Wistar albino rats    IR renal injury model   Udenafil\                 PRE      60 min and\                                                        ↑BUN, ↑sCr\         ↓BUN, ↓sCr\                                                                                                                 POS
                                                                                             *Orally:* 10 mg/kg\                24 h\                                                              ↑MDA, ↑NGAL         ↓MDA, ↓NGAL\                                                                                                                
                                                                                             1 h prior to clamping              after reperfusion                                                                      Lowest pathological damage rates                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; BUN, blood urea nitrogen; cGMP, cyclic guanosine monophosphate; GFR, glomerular filtration rate; IR renal, ischemia/reperfusion; MAP, mean arterial pressure; MDA, malondialdehyde; MMP9, Matrix metallopeptidase 9; NGAL, neutrophil gelatinase-associated lipocalin; PDE5I, phosphodiesterase 5 inhibitor; sCr, serum creatinine; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; UNaV, urinary sodium excretion; UUO, unilateral ureteral obstruction; ↓, reduced; ↑, increased ⇔, no change.

jcm-09-01284-t007_Table 7

###### 

Main characteristics of phosphodiesterase 5 inhibitors.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PDE5i            FDA Approved   Launch Date   Pharmacokinetics                    Recommended Dosage        Indications   Side Effects                Contraindications                                                                                                                                                                                                     Emerging and Other Off-Label Therapeutic Applications
  ---------------- -------------- ------------- ----------------------------------- ------------------------- ------------- --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sildenafil       **Yes**        1998          Cmax = 560 µg/L\                    ED: 25--100 mg OD\        ED\           Headache: 12.8%\            Absolute:\                                                                                                                                                                                                            Penile rehabilitation after Radical ProstatectomyHeart Failure/CVDHigh altitude illnessStroke/Neurodegenerative diseasesPeripheral neuropathyImproving fertilityPeripheral Arterial DiseaseRaynaud's syndromeDiabetic NephropathyAKICKDStuttering priapismPremature ejaculationUreteral stonesReyronie's diseaseFemale sexual dysfunctionOveractive bladderDiabetes mellitus
                                                Tmax = 0.8--1 h\                    PAH: 5--20 mg TDS         PAH           Flushing: 10.4%\            Any form of organic nitrate or NO donorsMyocardial infarction, stroke, or life-threatening arrhythmia within the last 6 monthsResting BP \<90/50 or \>170/100Unstable angina, angina with intercourse, CHF NYHA IV\   
                                                T1/2 = 2.6--3.7 h\                                                          Dyspepsia: 4.6%\            Relative:Known serious hypersensitivity reactionAntihypertensive medicationa-blockersDrugs that inhibit CYP34A                                                                                                        
                                                Affected by heavy/fatty meals                                               Nasal congestion: 1.1%\                                                                                                                                                                                                                           
                                                                                                                            Dizziness: 1.2%\                                                                                                                                                                                                                                  
                                                                                                                            Abnormal vision: 1.9%                                                                                                                                                                                                                             

  Tadalafil        **Yes**        2003          Cmax = 378 µg/L\                    ED: 10-20 mg on demand\   ED\           Headache: 14.5%\                                                                                                                                                                                                                                  
                                                Tmax = 2 h\                         ED: 5 mg OD\              PAH\          Flushing: 4.1%\                                                                                                                                                                                                                                   
                                                T1/2 = 17.5 h\                      LUTS: 5 mg OD\            LUTS          Dyspepsia: 12.3%\                                                                                                                                                                                                                                 
                                                Not affected by heavy/fatty meals   PAH: 40 mg                              Nasal congestion: 4.3%\                                                                                                                                                                                                                           
                                                                                                                            Dizziness: 2.3%\                                                                                                                                                                                                                                  
                                                                                                                            Back pain: 6.5%\                                                                                                                                                                                                                                  
                                                                                                                            Myalgia: 5.7%                                                                                                                                                                                                                                     

  Vardenafil       **Yes**        2003          Cmax = 18.7 µg/L\                   ED: 5--20 mg\             ED            Headache: 16%\                                                                                                                                                                                                                                    
                                                Tmax = 0.9 h\                       on demand\                              Flushing: 12%\                                                                                                                                                                                                                                    
                                                T1/2 = 3.9 h\                                                               Dyspepsia: 4%\                                                                                                                                                                                                                                    
                                                Affected by heavy/fatty meals                                               Nasal congestion: 10%\                                                                                                                                                                                                                            
                                                                                                                            Dizziness: 2%\                                                                                                                                                                                                                                    
                                                                                                                            Abnormal vision: \< 2%                                                                                                                                                                                                                            

  Avanafil         **Yes**        2013          Cmax = 5.2 µg/L\                    ED: 50--200 mg\           ED            Headache: 9.3%\                                                                                                                                                                                                                                   
                                                Tmax = 0.5--0.75 h\                 on demand                               Flushing: 3.7%\                                                                                                                                                                                                                                   
                                                T1/2 = 6--17 h\                                                             Dyspepsia: uncommon\                                                                                                                                                                                                                              
                                                Affected by heavy/fatty meals                                               Nasal congestion 1.9%\                                                                                                                                                                                                                            
                                                                                                                            Dizziness: 0.6%\                                                                                                                                                                                                                                  
                                                                                                                            Back pain: \< 2%\                                                                                                                                                                                                                                 
                                                                                                                            Myalgia: \< 2%                                                                                                                                                                                                                                    

  Udenafil         **No**         2005          Cmax = 1137 µg/L\                   ED: 100 mg\               ED            Headache: 2--9%\                                                                                                                                                                                                                                  
                                                Tmax = 0.76 h\                      on demand                               Flushing: 11--23%\                                                                                                                                                                                                                                
                                                T1/2 = 9.88 h                                                               Dyspepsia: uncommon\                                                                                                                                                                                                                              
                                                                                                                            Nasal congestion: 4--7%\                                                                                                                                                                                                                          
                                                                                                                            Red eye: 4--7%\                                                                                                                                                                                                                                   
                                                                                                                            Chest discomfort: 0--5%                                                                                                                                                                                                                           

  Lodenafil        **No**         2007          Cmax = 157 µg/L\                    ED: 80 mg\                ED            Headache: 15--22%\                                                                                                                                                                                                                                
                                                Tmax = 1.2 h\                       on demand                               Flushing: 5--6%\                                                                                                                                                                                                                                  
                                                T1/2 = 2.4 h                                                                Dyspepsia: 5--22%\                                                                                                                                                                                                                                
                                                                                                                            Nasal congestion: 5--11%\                                                                                                                                                                                                                         
                                                                                                                            Abnormal vision: 5--6%                                                                                                                                                                                                                            

  Mirodenafil      **No**         2011          Cmax = 2989 µg/L\                   ED: 80 mg\                ED            Headache: 8--11%\                                                                                                                                                                                                                                 
                                                Tmax = 1.4 h\                       on demand                               Flushing: 10--16%\                                                                                                                                                                                                                                
                                                T1/2 = 2.5 h                                                                Dyspepsia: 3%\                                                                                                                                                                                                                                    
                                                                                                                            Red eye: 3--4%\                                                                                                                                                                                                                                   
                                                                                                                            Chest discomfort: 0--3%                                                                                                                                                                                                                           

  Benzamidenafil   **No**         \-            ID                                  ID                        ID            ID                          ID                                                                                                                                                                                                                    ID

  Dasantafil       **No**         \-            ID                                  ID                        ID            ID                          ID                                                                                                                                                                                                                    ID

  Icariin          **No**         \-            ID                                  ID                        ID            ID                          ID                                                                                                                                                                                                                    ID

  Zaprinast        **No**         \-            ID                                  ID                        ID            ID                          ID                                                                                                                                                                                                                    ID
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; BP, blood pressure; Cmax, serum maximum concentration; CHF, chronic heart failure; CKD, chronic kidney disease; CVD, cardiovascular disease; ED, erectile dysfunction; ID, insufficient data; NO, nitric oxide; NYHA, New York Heart Association; OD, once daily; PAH, pulmonary arterial hypertension; PDE5I, phosphodiesterase 5 inhibitor; Tmax, transport maximum.

[^1]: Equal contribution of authors.
